

Medical Nutrition Therapy in Obesity Management

Jennifer Brown RD MScⁱ CBE, Carol Clarke RD MHScⁱⁱ,
Carlene Johnson Stoklossa RD MScⁱⁱⁱ, John Sievenpiper MD PhD^{iv}

- i) The Ottawa Hospital Bariatric Centre of Excellence
- ii) Private practice
- iii) Alberta Health Services
- iv) Faculty of Medicine, University of Toronto

Cite this Chapter

Brown J, Clarke C, Johnson Stoklossa C, Sievenpiper J. Canadian Adult Obesity Clinical Practice Guidelines: Medical Nutrition Therapy in Obesity Management. Available from: <https://obesitycanada.ca/guidelines/nutrition>. Accessed [date].

Update History

Version 2, October 21, 2022. Adult Obesity Clinical Practice Guidelines are a living document, with only the latest chapters posted at obesitycanada.ca/guidelines.

KEY MESSAGES FOR HEALTHCARE PROVIDERS

- Healthy eating is important for all Canadians, regardless of body size, weight or health status. Key messages from *Canada's Food Guide for Healthy Eating* can be used as a foundation for nutrition and food-related education. Use evidence-based nutrition resources to give your patients nutrition and behaviour-change advice that aligns with their values, preferences and social determinants of health (Figure 1).
- There is no one-size-fits-all eating pattern for obesity management. Adults living with obesity may consider various nutrition intervention options that are client-centred and flexible. Evidence suggests this approach will better facilitate long-term adherence (Table 1, Figure 2).
- Nutrition interventions for obesity management should focus on achieving health outcomes for chronic disease risk reduction and quality of life improvements, not just weight changes. Table 2 outlines health-related outcomes to support patients/clients in obesity management.
- Nutrition interventions for obesity management should emphasize individualized eating patterns, food quality and a healthy relationship with food. Including mindfulness-based eating practices that may help lower food cravings, reduce reward-driven eating, improve body satisfaction and improve awareness of hunger and satiety.
- Caloric restriction can achieve short-term reductions in weight (i.e., < 12 months) but has not shown to be sustainable long-term (i.e., > 12 months). Caloric restriction may affect neurobiological pathways that control appetite, hunger, cravings and body weight regulation that may result in increased food intake and weight gain.
- People living with obesity are at increased risk for micronutrient deficiencies including but not limited to vitamin D, vitamin B12 and iron deficiencies. Restrictive eating patterns and obesity treatments (e.g. medications, bariatric surgery) may also result in micronutrient deficiencies and malnutrition. Assessment including biochemical values can help inform recommendations for food intake, vitamin/mineral supplements and possible drug-nutrient interactions.
- Collaborate care with a registered dietitian who has experience in obesity management and medical nutrition therapy. Dietitians can support people living with obesity who also have other chronic diseases, malnutrition, food insecurity or disordered patterns of eating.
- Future research should use nutrition-related outcomes and health behaviours in addition to weight and body composition outcomes. Characterization of population sample collections should use the updated definition of obesity as “a complex chronic disease in which abnormal or excess body fat (adiposity) impairs health, increases the risk of long-term medical complications and reduces lifespan” rather than BMI exclusively. Qualitative data is needed to understand the lived experience of people with obesity.

RECOMMENDATIONS

1. We suggest that nutrition recommendations for adults of all body sizes should be personalized to meet individual values, preferences and treatment goals to support a dietary approach that is safe, effective, nutritionally adequate, culturally acceptable and affordable for long-term adherence (Level 4, Grade D).⁵
2. Adults living with obesity should receive individualized medical nutrition therapy provided by a registered dietitian (when available) to improve weight outcomes (body weight, BMI), waist circumference, glycemic control, established lipid, and blood pressure targets (Level 1a, Grade A).⁶
3. Adults living with obesity and impaired glucose tolerance (prediabetes) or type 2 diabetes may receive medical nutrition therapy provided by a registered dietitian (when available) to reduce body weight and waist circumference and improve glycemic control and blood pressure. (Level 2a, Grade B).^{7,8}
4. Adults living with obesity can consider any of the multiple medical nutrition therapies to improve health-related outcomes, choosing the dietary patterns and food-based approaches that support their best long-term adherence:
 - a. Calorie-restricted dietary patterns emphasizing variable macronutrient distribution ranges (lower, moderate, or higher carbohydrate with variable proportions of protein and fat) to achieve similar body weight reduction over 6–12 months (Level 2a, Grade B).⁹
 - b. Mediterranean dietary pattern to improve glycemic control, HDL-cholesterol and triglycerides (Level 2b, Grade C),¹⁰ reduce cardiovascular events (Level 2b, Grade C),¹¹ reduce risk of type 2 diabetes; (Level 2b, Grade C),^{12,13} and increase reversion of metabolic syndrome (Level 2b, Grade C)¹⁴ with little effect on body weight and waist circumference (Level 2b, Grade C).¹⁵
 - c. Vegetarian dietary pattern to improve glycemic control, established blood lipid targets, including LDL-C, and reduce body weight, (Level 2a, Grade B),¹⁶ risk of type 2 diabetes (Level 3, Grade C)¹⁷ and coronary heart disease incidence and mortality (Level 3, Grade C).¹⁸
 - d. Portfolio dietary pattern to improve established blood lipid targets, including LDL-C, apo B, and non-HDL-C (Level 1a, Grade B),¹⁹ CRP, blood pressure, and estimated 10-year coronary heart disease risk (Level 2a, Grade B).¹⁹
 - e. Low-glycemic index dietary pattern to reduce body weight (Level 2a, Grade B)²⁰ glycemic control, (Level 2a, Grade B),²¹ established blood lipid targets, including LDL-C (Level 2a, Grade B),²² and blood pressure (Level 2a, Grade B)²³ and the risk of type 2 diabetes (Level 3, Grade B) and coronary heart disease (Level 3, Grade C).²⁵
 - f. Dietary Approaches to Stop Hypertension (DASH) dietary pattern to reduce body weight and waist circumference; (Level 1a, Grade B),²⁶ improve blood pressure (Level 2a, Grade B),²⁷ established lipid targets, including LDL-C (Level 2a, Grade B),²⁷ CRP (Level 2b, Grade B),²⁸ glycemic control; (Level 2a, Grade B),²⁷ and reduce the risk of diabetes, cardiovascular disease, coronary heart disease, and stroke (Level 3, Grade C).²⁷
 - g. Nordic dietary pattern to reduce body weight (Level 2a, Grade B)²⁹ and body weight regain (Level 2b, Grade B)³⁰ improve blood pressure (Level 2b, Grade B)³⁰ and established blood lipid targets, including LDL-C, apo B, (Level 2a, Grade B),³¹ non-HDL-C (Level 2a, Grade B)³² and reduce the risk of cardiovascular and all-cause mortality (Level 3, Grade C).³³
 - h. Partial meal replacements (replacing one to two meals/day as part of a calorie-restricted intervention) to reduce body weight, waist circumference, blood pressure and improve glycemic control (Level 1a, Grade B).³⁴ (Refer to Appendix for updated references)
 - i. Intermittent or continuous calorie restriction achieved similar short-term body weight reduction (Level 2a, Grade B).³⁵ (Refer to Appendix for updated references)
 - j. Pulses (i.e. beans, peas, chickpeas, lentils) to improve body weight (Level 2, Grade B)³⁶ improve glycemic control, (Level 2, Grade B),³⁷ established lipid targets, including LDL-C, (Level 2, Grade B),³⁸ systolic BP (Level 2, Grade C),³⁹ and reduce the risk of coronary heart disease (Level 3, Grade C).⁴⁰
 - k. Vegetables and fruit to improve diastolic BP (Level 2, Grade B),⁴¹ glycemic control (Level 2, Grade B),⁴² reduce the risk of type 2 diabetes (Level 3, Grade C)⁴³ and cardiovascular mortality (Level 3, Grade C).⁴⁴
 - l. Nuts to improve glycemic control, (Level 2, Grade B)⁴⁵ established lipid targets, including LDL-C (Level 3, Grade C),⁴⁶ and reduce the risk of cardiovascular disease (Level 3, Grade C).⁴⁷
 - m. Whole grains (especially from oats and barley) to improve established lipid targets, including total cholesterol and LDL-C (Level 2, Grade B).⁴⁸
 - n. Dairy foods to reduce body weight, waist circumference, body fat and increase lean mass in calorie-restricted diets but not in unrestricted diets (Level 3, Grade C)⁴⁹ and reduce the risk of type 2 diabetes and cardiovascular disease (Level 3, Grade C).⁴³

5. Adults living with obesity and impaired glucose tolerance (prediabetes) should consider intensive behavioural interventions that target a 5%–7% weight loss to improve glycemic control, blood pressure and blood lipid targets (Level 1a, Grade A),⁵⁰ reduce the incidence of type 2 diabetes, (Level 1a, Grade A),⁵¹ microvascular complications (retinopathy, nephropathy, and neuropathy) (Level 1a Grade B)⁵² and cardiovascular and all-cause mortality (Level 1a, Grade B).⁵²
6. Adults living with obesity and type 2 diabetes should consider intensive behavioural therapy that target a 7%–15%

weight loss to increase the remission of type 2 diabetes (Level 1a, Grade A)⁵³ and reduce the incidence of nephropathy (Level 1a, Grade A)⁵⁴ obstructive sleep apnea (Level 1a, Grade A),⁵⁵ and depression (Level 1a, Grade A).⁵⁶

7. We recommend a non-dieting approach to improve quality of life, psychological outcomes (general well-being, body image perceptions), cardiovascular outcomes, body weight, physical activity, cognitive restraint and eating behaviours (Level 3, Grade C).⁵⁷

KEY MESSAGES FOR PEOPLE LIVING WITH OBESITY

- Nutrition is important for everyone, regardless of body size or health. Your health is not a number on a scale. When you are ready to make a change, choose behaviour-related goals to improve your nutrition status and health (medical, functional, emotional health) (Table 2).
- There is no one-size-fits-all healthy eating pattern. Choose an eating pattern that supports your best health and one that can be maintained over time, rather than a short-term “diet.” Talk to your healthcare provider to discuss the advantages and disadvantages of different eating patterns to help achieve your health-related goals.
- How you eat is as important as what and how much you eat. Practice eating mindfully and promote a healthy relationship with food.
- “Dieting” or severely restricting the amount you eat may cause changes to your body that can lead to weight regain over time.
- See a registered dietitian for an individualized approach and ongoing support for your nutrition and health-related needs.

Introduction

People living with obesity¹ and people with larger bodies are often stigmatized and scrutinized for their food choices, portions and eating behaviours.^{1–3} Much of the social marketing efforts, public health and clinical messaging around food and eating behaviours has focused on “eating less” or choosing “good” foods. As a result of these messages, dieting and weight-loss focused outcomes perpetuate the notion that weight loss and/or “health” can be achieved purely by caloric restriction, food deprivation and/or “dieting” practices. These simplistic narratives often neglect the evidence that weight loss may not be sustainable long-term, not because of personal choices or lack of willpower, but rather from strong biological or physiological mechanisms that protect the body against weight loss. The diet industry and weight loss focused research field has thus falsely advertised diet or food and eating habits as the culprit for weight gain, contributing to the bias and stigma reviewed in the *Reducing Weight Bias in Obesity Management Practice and Policy* chapter. A paradigm shift is needed in all aspects of nutrition and eating behaviour research, policies, education and health promotion to support people of all weights, body shapes and sizes to eat well without judgment, criticism or bias regarding food and eating behaviours.

This chapter provides evidence-informed information on nutrition interventions conducted in clinical and/or epidemiological studies in the context of obesity management for adults. Caution is

needed when interpreting much of the nutrition-specific evidence as weight loss is often a primary outcome in nutrition-related studies, and most studies have used the definition of obesity according to body mass index (BMI) classifications instead of the current definition (Obesity is a chronic, progressive and relapsing disease characterized by the presence of adiposity that impairs health and social well-being) reviewed in the summary article of these guidelines (published in the *Canadian Medical Association Journal*) chapter and the *Assessment of People Living with Obesity* chapter. Recommendations and key messages in this chapter are specific for people living with obesity and may not be applicable or appropriate for people with larger bodies who do not have health impacts from their weight. Furthermore, this chapter is specific for primary care providers (i.e., general practitioners) and to support coordination of care with regulated nutrition professionals in Canada (i.e., registered dietitians [RD] or registered dietitian/nutritionist [RDN], diététistes [Dt.P. or P.Dt.]). Future research should assess nutrition-related outcomes, health-related outcomes and behaviour changes instead of weight loss outcomes alone across all weight spectrums.

Traditional nutrition interventions for obesity have focused on strategies that promote weight loss through dietary restriction. Although a caloric deficit is required to initiate weight loss, sustaining lost weight may be difficult long term due to compensatory

mechanisms that promote positive calorie intake by increasing hunger and the drive to eat.⁶⁴⁻⁶⁶ Providers, policy makers, patients/clients and the general public should be aware that nutrition interventions affect everyone differently, and therefore there is no one best nutrition approach or intervention.⁶⁷ As such, some people may favour an approach that is macronutrient-based (consisting of higher, moderate or lower intake of carbohydrates, protein and/or fat), caloric restricted, food-based or non-dieting. Nutrition and healthy eating are important to the health and well-being of all Canadians, regardless of weight, body size or health status. In the context of obesity management, the best nutrition approach is one an individual can maintain long term to achieve health-related and/or weight-related outcomes.⁹ Table 1 and Figure 2 provide an overview of the various nutrition interventions used to influence weight change, health and quality of life indicators, as well as advantages and disadvantages of each.

Individualized medical nutrition therapy

Nutrition interventions should use a shared decision-making approach to improve overall health, promote a healthy relationship with food, consider the social context of eating and promote eating behaviours that are sustainable and realistic for the individual. An RD should be involved in the assessment, delivery and evaluation of care wherever possible. MNT provided by a registered dietitian has demonstrated improvements in weight outcomes (body weight and BMI), waist circumference, glycemic control, reduction in LDL-C, triglycerides and blood pressure.⁶⁻⁸

Systematic reviews and meta-analyses of randomized controlled trials have shown that individualized nutrition consultation by a registered dietitian decreases weight by an additional -1.03 kg and BMI by -0.43 kg/m² in participants with BMI ≥ 25 kg/m² compared with usual care or written documentation.⁶ In adults living with type 2 diabetes, MNT by a registered dietitian resulted in significant reductions of HgA1c, weight, BMI, waist circumference, cholesterol and systolic blood pressure reported by systematic reviews and meta-analyses.⁸ In addition, MNT delivered by an RD to individuals and/or group-based sessions for the prevention of type 2 diabetes has also found a weight loss range of -1.5 to -13 kg (3–26% weight loss) with a pooled effect of -2.72 kg by meta-analysis.⁷ Table 1 provides outcomes measures for weight and health parameters when using individualized MNT by an RD.

Nutrition interventions

Nutrition interventions that are safe, effective, nutritionally adequate, culturally acceptable and affordable for long-term adherence should be considered for adults living with obesity.⁵ Healthcare providers should adapt nutrition interventions and/or adjunct therapy to meet their patient/clients' individual values, preferences and treatment goals. However, to date, no single best nutrition intervention has been shown to sustain weight loss long-term, and literature continues to support the importance of long-term adherence, regardless of the intervention.^{9,68}

Definitions of Terms Used in This Chapter

Obesity: Historically, obesity has been defined using a body mass index (BMI) of ≥ 30 kg/m². The [Assessment of People Living with Obesity](#) chapter reviews the limitations and biases associated with using this BMI definition. Although increased body fat can have important implications for health and well-being, the presence of increased body fat alone does not necessarily imply or reliably predict ill health. For this reason, evidence reviewed in this chapter that included participants with overweight or obesity using BMI categories (≥ 25 kg/m² or ≥ 30 kg/m², respectively) without any reported adiposity-related health and social well-being impairments are referred to as “people with a BMI ≥ 25 kg/m²” (descriptive characteristics of size, not health). The Canadian Adult Obesity Clinical Practice Guidelines define obesity as “a complex chronic disease in which abnormal or excess body fat (adiposity) impairs health, increases the risk of long-term medical complications and reduces lifespan.” We use this definition rather than weight or BMI by referring to “adults living with obesity” using people-first language¹ and in support of changing the narrative about obesity.^{3,4} We recognize that this may be controversial and acknowledge that further research is needed to compare nutrition interventions using new definitions of obesity; however a diagnosis of obesity in clinical practice requires a comprehensive assessment to mitigate unintentional weight bias or stigma that may exist if using BMI alone.

Obesity management: The term “obesity management” is used to describe health-related improvements beyond weight-loss outcomes alone. If weight loss occurred as a result of the intervention, this should not be the focus over the health and quality of life (QoL) improvements.

Medical Nutrition Therapy: Medical nutrition therapy (MNT) is an evidence-based approach used in the nutrition care process (NCP) of treating and/or managing chronic diseases, often used in clinical and community settings, that focuses on nutrition assessment, diagnostics, therapy and counselling. MNT is often implemented and monitored by a registered dietitian and/or in collaboration with physicians and regulated nutrition professionals. For these guidelines, MNT will be used as a standard language in nutritional therapeutic approaches for obesity interventions.

Nutrition interventions: This term is used instead of “diet” to refer to evidence-based, nutrition-related approaches for improving health outcomes instead of weight-loss focused ideals that are often associated with the term “diet.”

Caloric restriction

Studies on caloric restriction generally fall into three categories: moderate calorie (1300–1500 kcal/day), low-calorie (900–1200 kcal/day) and very low-calorie (< 900 kcal/day), with intervention periods ranging from three months to three years.

A randomized clinical trial of women (25–75 years old) with BMI 37.84 +/- 3.94 kg/m² found prescribing 1000 versus 1500 kcal/day along with behavioural treatment produced greater weight loss at six months, but there was significant weight regain at 12 months as compared with the 1500 kcal/day group.⁶⁹ At 12 months, a significantly greater percentage of participants prescribed 1000 kcal/day had body weight reductions of 5% or more than those assigned 1500 kcal/day.⁶⁹ However, a 1000 kcal/day prescription may be more difficult to sustain, especially for individuals for whom the caloric reduction is 50% or more from their usual intake.⁶⁹

A randomized clinical trial of older adults (≥ 65 years old) who were advised to reduce their caloric intake by 500 kcal/day below their estimated caloric needs with a minimum intake of 1000 kcal/day had a significant decrease in body weight (4%) at 12 months, as well as significant improvements in blood glucose and HDL-cholesterol.⁷⁰

A systematic review and meta-analysis of randomized control trials using very low-calorie diets (VLCD), with or without meal replacements, for weight loss found using a VLCD within a behavioural weight loss program produced greater weight loss at 12 months (-3.9 kg) and 24 months (1.4 kg) than a behavioural program alone.⁷¹ There was no evidence a VLCD intervention without behavioural support is effective.⁷¹

Although MNT that achieves a caloric deficit can result in weight loss in the short-term (6–12 months), the weight change is often not sustained over time. Furthermore, the common recommendation that a caloric deficit of 500 kcal/day or 3500 kcal/week would produce 1 lb (0.45 kg) of weight loss is not valid, in that weight loss is not linear.^{72,73} Polidori and colleagues first quantified the amount of calorie intake compensated for weight loss changes in free living humans and estimated that appetite increased by ~100 kcal/day for every kilogram of weight lost, contributing to weight gain over time.⁷⁴ Caloric restriction may in some individuals lead to pathophysiological drivers to promote weight gain via increased hunger, appetite and decreased satiety.⁶⁶ In addition, caloric restrictions may have negative consequences for skeletal health⁷⁵ and muscle strength,⁷⁶ contributing to the role of individualizing nutrition interventions that are safe, effective and meet the values and preferences of the patient/client. Indirect calorimetry should be considered if energy expenditure and/or caloric targets are indicated.⁵⁸

Macronutrient-based approaches

Macronutrients are the main source of calories in the diet. The dietary reference intakes (DRIs) are a comprehensive set of nutrient reference values for healthy populations that can be used

for assessing and planning eating patterns. (For more information, refer to: <https://www.canada.ca/en/health-canada/services/food-nutrition/healthy-eating/dietary-reference-intakes.html>) The dietary reference intakes permit wide acceptable macronutrient distribution ranges. They allow, for example, 45% to 65% of calories from carbohydrate, 10% to 35% of calories from protein and 20% to 35% of calories from fat (with 5% to 10% of calories derived from linoleic acid and 0.6% to 1.2% of calories derived from alpha linolenic acid).⁷⁷

Several macronutrient-based approaches have been investigated within and outside these ranges. Researchers have evaluated, for instance, low carbohydrate diets that substitute fat and protein at the expense of carbohydrate but include adequate protein (15%–20% of calories). Studies have also investigated extremely low-carbohydrate (≤10% of calories) variants, including variants like the ketogenic diet which are extremely high in fat (≥75% of calories). No meaningful advantages of one macronutrient distribution over another have reliably been shown. A network meta-analysis was undertaken of 48 randomized controlled trials (involving 7,286 participants) that provided dietary advice to consume varying macronutrient distributions under free-living conditions. This meta-analysis showed no differences in weight loss at six months and 12 months of follow-up between diets categorized broadly by their macronutrient distribution as low carbohydrate, moderate-macronutrient, or low-fat, or categorized by their 11 popular diet names encompassing a wide range of distributions.⁹ Subsequent large randomized controlled trials have confirmed these findings.⁷⁸

The lack of meaningful differences between different macronutrient distributions has been shown to extend to cardiometabolic risk factors. Systematic reviews and meta-analyses of randomized trials have investigated glycemic control in people with diabetes (inclusive of people with BMI ≥25 kg/m²). These trials have failed to show that the early improvements seen in glycemic control at six months are sustained at 12 months on low-carbohydrate diets (≤40% of calories from carbohydrate or 21g–70g) in which the carbohydrate has been replaced with fat and/or protein.⁷⁹ Researchers have also assessed the effects of low-carbohydrate diets that replace carbohydrate with protein in people with or without diabetes who have a BMI ≥25 kg/m². They report a similar attenuation of effects on fasting blood glucose and triglycerides and lack of effect on blood pressure and C-reactive protein over follow-up periods that extend beyond 12 months.⁸⁰ Any improvements in triglycerides and HDL-C have also been found to come at the expense of increases in the more atherogenic and established lipid targets for cardiovascular risk reduction, LDL-C, non-HDL-C and apo B.^{79,81} According to available randomized controlled trials, the most important determinants of achieving any benefit over the long-term are adherence to any one macronutrient distribution and clinic attendance.^{9,80,82,83}

This data from randomized controlled trials is supported by evidence from large prospective cohort studies that allow macronutrient exposures to be assessed in relation to downstream clinical outcomes of cardiometabolic diseases. No single approach

appears superior, with harm observed at the extremes of intake. A systematic review and meta-analysis were undertaken of five prospective cohort studies involving 432,179 participants over a median follow-up of 25 years. The evidence showed a U-shaped relationship between carbohydrate and mortality, with lower-carbohydrate (< 40% of calories) and higher carbohydrate (>70% of calories) diets associated with increased mortality, and the wide range between (40–70% of calories) associated with lower mortality.⁸⁴ The Prospective Urban and Rural Epidemiological (PURE) cohort study involved 135,335 participants from 18 low-, middle- and high-income countries; the participants were free of cardiovascular disease. PURE did not show an adverse association with lower-carbohydrate interventions, an demonstrated only that higher carbohydrate interventions (>70% of calories) were associated with increased cardiovascular and all-cause mortality over 10 years of follow-up.⁸⁵

The quality of the macronutrients substituted appears to be a more important consideration than the quantity. The Eco-Atkins randomized trial showed that a lower-carbohydrate intervention (26% of total calories) reduced LDL-C in 47 participants with BMI >27 kg/m² and hyperlipidemia over four weeks, during which foods were provided, and another six months during which foods were self-selected.^{86,87} This intervention replaced refined, high-glycemic index carbohydrate sources with high-quality unsaturated fat from nuts and canola oil and plant-based protein from soy and pulses.

Systematic reviews and meta-analyses of randomized controlled trials of interventions that focus on the quality of the fat or protein separately have also shown advantages. Researchers have also investigated isocaloric replacement of refined carbohydrate sources with high-quality monounsaturated fatty acids (MUFAs) from canola oil and olive oil⁸⁸ or animal protein with sources of plant-based protein.^{89,90} These studies have shown improvements in multiple cardiometabolic risk factors in people with diabetes and a BMI \geq 25 kg/m², over average follow ups of 19 weeks and eight weeks, respectively.⁸⁸ Similarly, dairy whey protein supplements substituted for largely other protein sources and/or carbohydrate have shown reductions in body weight and fat mass, and improvements in blood pressure, blood glucose and blood lipids over follow-up ranging from two weeks to 15 months in people with BMI \geq 25 kg/m².⁹¹ Other systematic reviews and meta-analyses of randomized cardiovascular outcomes trials have shown that the beneficial effect of low saturated fatty acids (SFAs) diets on cardiovascular events is restricted to the replacement of saturated fatty acids with polyunsaturated fatty acids,⁹² especially mixed n-3/n-6 sources such as soybean oil and canola oil.⁹³

The importance of the quality of macronutrients has been seen in the observational evidence from prospective cohort studies. Pooled analyses of the Harvard prospective cohort studies and large individual prospective cohort studies have evaluated the incidence of cardiovascular disease. These analyses suggest that replacement of SFAs with high-quality sources of MUFAs (from olive oil, canola oil, avocado, nuts and seeds) and high-quality sources of carbohydrates (from whole grains and low-glycemic index carbohydrate foods) is associated with decreased incidence of coro-

nary heart disease.^{94,95} Whereas the substitution of animal fat or animal protein for carbohydrate was associated with an increase in mortality, the replacement of carbohydrate with plant-based unsaturated fats and protein is shown to be associated with a reduction in mortality.⁸⁴ The source of carbohydrate has also been shown to be important. An analysis of the PURE study showed that the source of carbohydrate may modify the association. The highest intake of carbohydrate (from sources such as legumes and fruit) was associated with lower cardiovascular mortality and all-cause mortality.⁹⁶

Taken together, the available evidence related to macronutrients suggests that there is a wide range of acceptable intakes, emphasizing the role of individualized MNT. The data also suggest that quality may be a more important focus than quantity in the evaluation of the relationship between macronutrient distributions and cardiometabolic outcomes. This theme is reflected in the subsequent discussions of dietary patterns and food-based approaches.

Dietary fibre

High intakes of dietary fibre are recommended for the general population. The DRIs have set an adequate intake (AI) for total fibre from naturally occurring, added or supplemental sources of 25 g/day and 38 g/day for women and men 19–50 years of age, respectively, and 21 g/day and 30 g/day for women and men \geq 51 years of age, respectively.⁷⁷ Several advantages have been shown for dietary fibre. The World Health Organization (WHO) commissioned a series of systematic reviews and meta-analyses of prospective cohort studies, inclusive of people without acute or chronic diseases (including individuals with prediabetes, mild to moderate hypercholesterolaemia, mild to moderate hypertension, or metabolic syndrome). The evidence showed that higher intakes of total dietary fibre were associated with decreased incidence of diabetes, coronary heart disease and mortality, stroke and mortality, colorectal cancer, and total cancer and mortality. The authors did not observe differences in risk reduction by fibre type (insoluble, soluble or soluble viscous) or fibre source (cereals, fruit, vegetables or pulses).⁹⁷ Meta-regression dose response analyses showed that benefits were associated with intakes greater than 25 g–29 g per day.⁹⁷ Similar results have been shown in systematic reviews and meta-analyses of prospective cohort studies that did not exclude people with diabetes.⁹⁸

Despite the lack of interaction by fibre type and source in the prospective cohort studies, the evidence from randomized controlled trials differs. This data supports the benefits of dietary fibre on intermediate cardiometabolic risk factors and suggests these are restricted largely to fibre from a soluble viscous fibre. Soluble viscous fibre is the only fibre supported by Health Canada with approved health claims for lowering cholesterol from oats, barley, psyllium and polysaccharide complex (glucomannan, xanthan gum, sodium alginate),^{99–101} and postprandial glycemia in the case of the polysaccharide complex (glucomannan, xanthan gum, sodium alginate).¹⁰² Systematic reviews and meta-analyses of randomized controlled trials have evaluated specific types of soluble viscous fibre. The evidence from oats (beta-glucan), barley (beta-glucan),

psyllium, konjac mannan (glucomannan) and fruit and vegetables (pectin) shows improved glycemic control by HbA1c and fasting blood glucose, insulin resistance by HOMA-IR, blood pressure, and blood lipids, including the established therapeutic lipid targets LDL-C, non-HDL-C and apo B.^{103–108} The studies also highlighted that insoluble fibre, other than contributing to stool bulking,¹⁰⁹ has not shown cardiometabolic advantages in comparison with low-fibre controls or in direct comparisons with viscous soluble fibre, where it is often used as a neutral comparator of soluble viscous fibre.^{110–113}

Mixed fibre interventions emphasizing high intakes of dietary fibre from a combination of types (insoluble, soluble, and soluble viscous) and sources (cereals, fruit, vegetables and/or pulses), however, have shown cardiometabolic advantages. The WHO commissioned a series of systematic reviews and meta-analyses of randomized controlled trials inclusive of people without acute or chronic diseases (including individuals with prediabetes, mild to moderate hypercholesterolaemia, mild to moderate hypertension, or metabolic syndrome), and earlier pooled analyses of randomized and non-randomized controlled trials in people with diabetes have evaluated mixed fibre interventions. These have shown that mixed fibre interventions result in reductions in body weight and improvements in HbA1C, postprandial glycemia, blood pressure and blood lipids.^{97,114} Dose thresholds for benefit are unclear but generally support optimal benefits at intakes of ≥ 25 g/day of total fibre in mixed fibre interventions providing 10 g/day to 20 g/day of soluble viscous fibre.^{97,114}

Low-calorie sweeteners

Recent syntheses of the evidence for low-calorie sweeteners and health outcomes have come to different conclusions. Important sources of disagreement appear to be the failure to account for the nature of the comparator in the interpretation of randomized controlled trials and the high risk of reverse causality in the models favoured by prospective cohort studies.^{115–117}

Systematic reviews and meta-analyses of randomized controlled trials and individual randomized controlled trials investigating the effect of low-calorie sweeteners in substitution for water, placebo or matched weight-loss diets (conditions under which there is no caloric displacement) have not shown weight loss or improvements in cardiometabolic risk factors,^{118,119} with few exceptions.¹²⁰

Systematic reviews and meta-analyses of randomized controlled trials and individual randomized controlled trials have also evaluated the effect of the intended substitution of low-calorie sweeteners for sugars or other caloric sweeteners (conditions under which there is caloric displacement, usually from sugar-sweetened beverages). This research has shown the expected modest weight loss and attendant improvements in cardiometabolic risk factors (blood glucose, blood pressure and liver fat) in people with BMI ≥ 25 kg/m².^{119,121–123} Similar disagreements are seen depending on the models used in the prospective cohort studies.

Systematic reviews and meta-analyses of prospective cohort studies and individual large prospective cohort studies that have

modelled baseline or prevalent intake of low-calorie sweeteners have shown an association with weight gain and an increased incidence of diabetes and cardiovascular disease.^{118,119} Other studies have used analytical approaches to mitigate reverse causality by modelling change in intake or substitution of low-calorie sweetened beverages for sugar-sweetened beverages. This research has reported associations with weight loss and a decreased incidence of diabetes, cardiovascular disease, and all-cause mortality^{116,124,125} in populations inclusive of people with BMI ≥ 25 kg/m². Taken together, these different lines of evidence indicate that low-calorie sweeteners in substitution for sugars or other caloric sweeteners, especially in the form of sugar-sweetened beverages, may have advantages like those of water or other strategies intended to displace excess calories from added sugars.

Dietary patterns

Several interventions using specific dietary patterns have shown advantages for weight loss and maintenance with improvements in cardiometabolic risk factors and associated reductions in obesity-related complications (Table 1). The Mediterranean dietary pattern is a plant-based dietary pattern that emphasizes a high intake of extra virgin olive oil, nuts, fruit and vegetables, whole grains and pulses; a moderate intake of wine, fish and dairy; and a low intake of red meats. This dietary pattern has shown weight loss and improvements in glycemic control and blood lipids compared with other dietary patterns in people with type 2 diabetes.¹⁰ These improvements have been reflected in benefits in important clinical outcomes. The PREvención con Dieta MEDiterránea (PREDIMED) study was a large Spanish multicentre randomized trial which was recently retracted and republished.¹¹ PREDIMED investigated a calorie-unrestricted Mediterranean dietary pattern, supplemented with either extra virgin olive oil or mixed nuts, compared with a control diet (calorie-unrestricted low-fat American Heart Association) in 7447 participants at high cardiovascular risk. More than 90% of the participants had a BMI ≥ 25 kg/m². The researchers concluded that the Mediterranean dietary pattern reduced major cardiovascular events by $\sim 30\%$, diabetes incidence by 53% (single-centre finding), and increased reversion of metabolic syndrome by $\sim 30\%$, with little effect on body weight over a median follow-up of 4.8 years.^{11–14,126}

Numerous other dietary patterns have been investigated for their effects on body weight, cardiometabolic risk factors, and obesity-related complications. These include:

- Low-glycemic index: A dietary pattern that emphasizes the exchange of low-glycemic index foods (temperate fruit, dietary pulses, heavy mixed grain breads, pasta, milk, yogurt, etc.) for high-glycemic index foods.^{20–25,127–129}
- Dietary approaches to stop hypertension (DASH): A dietary pattern emphasizing a high intake of fruit, low-fat dairy, vegetables, grains, nuts, and dietary pulses and a low intake of red meat, processed meat, and sweets.^{27,28}

- **Portfolio:** A plant-based dietary pattern emphasizing the intake of a portfolio of cholesterol-lowering foods (e.g. nuts; plant-based protein from soy and pulses; viscous fibre from oats, barley and psyllium; and plant sterols, plus MUFAs from extra virgin olive oil or canola oil), all of which have Food and Drug Administration (FDA), Health Canada and/or European Food Safety Authority approved health claims for cholesterol-lowering or cardiovascular disease risk reduction.¹⁹
- **Nordic:** A Nordic dietary translation of the Mediterranean, Portfolio, DASH and National Cholesterol Education Program dietary patterns. Nordic emphasizes foods typically consumed as part of a traditional diet in Nordic countries.^{29–33,130,131}
- **Vegetarian:** A plant-based dietary pattern that includes four main variants (lacto-ovo vegetarian, lacto vegetarian, vegetarian and vegan).^{16–18}

Systematic reviews and meta-analyses have shown that these different dietary patterns improved cardiometabolic risk factors in randomized controlled trials. They are associated with decreased incidence of diabetes and cardiovascular disease in large prospective cohort studies inclusive of people with a BMI ≥ 25 kg/m².

Meal replacements

Partial meal replacements are used to replace one to two meals per day as part of a calorie-restricted intervention. These calorie-restricted interventions have been shown to reduce body weight, waist circumference, blood pressure and glycemic control compared with conventional, calorie-restricted weight loss diets in a systematic review and meta-analysis of nine randomized control trials in people with a BMI ≥ 25 kg/m² and type 2 diabetes over a median follow-up of six months.³⁴ Another systematic review and meta-analysis of 23 randomized control trials reported programs that include partial meal replacements achieved greater weight loss at one year compared with weight loss programs without use of partial meal replacements, with or without behavioural change support.¹³² These results are consistent with an earlier meta-analysis.¹³³ At one year, attrition rates were high, but better for the partial meal replacement group compared with the calorie-restricted group (47% vs. 64%, respectively) with no adverse effects.¹³³

Meal replacements have also shown advantages as key features of intensive behavioural therapy programs targeting $\geq 5\%$ – 15% of weight loss. The largest comprehensive behavioural intervention in people with type 2 diabetes, the Look AHEAD (Action for Health in Diabetes) trial, targeted $\geq 7\%$ weight loss using meal replacements (with instruction to replace two meals per day with liquid meal replacements and one snack per day with a bar meal replacement) during weeks three to 19 on the intensive behavioural therapy. Higher adherence to the use of meal replacements was associated with approximately four-times greater likelihood of achieving the $\geq 7\%$ weight loss goal at one year, compared with participants with lower adherence at one year,¹³⁴ contributing to better glycemic control and less health-related complications over the 9.6

years of follow-up.^{50,54,56} The more recent Diabetes Remission Clinical Trial (DiRECT) included total liquid meal replacements for the first 12–20 weeks of the intensive behavioural therapy program. DiRECT showed a nearly 20-fold greater likelihood of achieving diabetes remission at 12 months of follow-up in participants living with obesity and type 2 diabetes.⁵³ Full meal replacements as part of intensive behavioural therapy programs are discussed in the [Commercial Products and Programs in Obesity Management](#) chapter.

VLCDs using meal replacements include medical supervision and extensive support (nutrition, psychological, exercise counselling) as part of the intervention. Long-term studies using VLCD interventions with partial meal replacements reported weight outcomes of -6.2% at year one and -2.3% at three years in those who attended over three years and did not have added pharmacotherapy treatment.¹³⁵ As previously reported, weight loss or weight cycling can lead to biological compensatory mechanisms that can promote long-term weight gain in some people.^{64–66} Despite lack of weight maintenance long term, without treatment, higher weight trajectories could be expected. Therefore, adding other treatments (e.g. pharmacotherapy and/or surgery for appetite regulation) over time could be considered to support obesity management rather than weight loss alone.

Note: In Canada, meal replacement products for use in calorie-restricted interventions are regulated by the Canadian Food and Drug Regulations. (https://laws-lois.justice.gc.ca/eng/regulations/c.r.c.,_c._870/FullText.html)

Intermittent fasting

Intermittent fasting includes a variety of meal timing approaches that alternate periods of extended fasting (no intake, or less than 25% of needs) and periods of unrestricted intake. Intermittent fasting is also described as time-restricted feeding, alternate-day fasting or intermittent energy restriction; however, there are multiple variations reported in the literature.⁵⁹ There was limited evidence in human physiology and metabolism studies. In a systematic review and meta-analysis of randomized controlled trials, Cioffi et al. (2018)³⁵ identified 11 trials (eight-24 weeks) which found comparable outcomes between interventions using intermittent energy restriction compared with continuous energy restriction (weight, fat mass, fat free mass, waist circumference, glucose, HbA1C, triglycerides and HDL-C). Intermittent energy restriction was identified to reduce fasting insulin levels (pooled difference -0.89 uU/mL) compared to controls; however, the study authors questioned the clinical significance of this as there were no differences in glucose, HbA1C or HOMA-IR. Adherence was similar between continuous and intermittent energy restriction groups, with higher attrition rates and adverse events in the intermittent energy restriction groups.³⁵ Similar results for weight loss and glycemic control were reported in two recent papers (one systematic review and meta-analysis, and a systematic review) published after the literature review for this chapter (June 2018).^{59,60}

Food-based approaches

Several dietary patterns emphasizing specific food-based approaches have shown advantages (Table 1). These include pulses (beans, peas, chickpeas, and lentils),^{36–40} fruit and vegetables,^{41,42,44} nuts,^{45–47,136–138} whole grains (especially from oats and barley)^{43,48,97,107,139,140} and dairy.^{49,141–143} These food-based approaches have shown weight loss and/or weight maintenance, with improvements in cardiometabolic risk factors, in randomized controlled trials. There is also evidence of associated reductions in the incidence of diabetes and cardiovascular disease in large prospective cohort studies inclusive of people with a BMI ≥ 25 kg/m².

Intensive behavioural therapy programs

Intensive behavioural therapy (IBT) programs consist of resource-intensive, comprehensive, multi-modal behavioural interventions that are delivered by interprofessional teams (e.g. physicians, RDs, nurses and kinesiologists). These programs combine nutrition interventions with increased physical activity. The intensity of follow-up varied from weekly to every three months, with gradually diminishing contact over the course of the program. ILI programs that target $\geq 5\%$ to 15% weight loss have shown sustained weight loss with marked improvements in cardiometabolic risk factors and obesity-related complications. Large, randomized controlled trials have shown that ILI programs improve glycemic control, blood pressure and blood lipids in adults living with obesity who have impaired glucose tolerance prediabetes^{144–146} or type 2 diabetes.⁵⁰ These randomized controlled trials have also shown important clinical benefits of ILI programs, including:

- Type 2 diabetes,^{51,52,144–147}
- Microvascular complications (retinopathy, nephropathy, and neuropathy),⁵²
- Cardiovascular mortality, and all-cause mortality in adults living with obesity who have impaired glucose tolerance;⁵² and
- Increases in the remission of type 2 diabetes;⁵³ and
- Reductions in the incidence of nephropathy,⁵⁴ obstructive sleep apnea⁵⁵ and depression⁵⁶ in adults with a BMI ≥ 25 kg/m² who have type 2 diabetes.

The available evidence suggests an overall benefit of different ILI programs in adults living with obesity. However, the feasibility of implementing these programs is dependent upon the availability of resources and access to an interprofessional team to achieve the target weight loss outcome (i.e., $\geq 5\%$ to 15%).

Non-dieting approaches

Non-dieting approaches include an umbrella of concepts described in the literature that offer healthcare providers alternatives

to weight-loss focused interventions.¹⁴⁸ These approaches often reject weight-loss or dieting practices and typically use concepts of mindfulness in response to internal hunger, satiety, cravings and appetite instead of caloric restriction or cognitive restraint. Components of a non-dieting approach may include the following concepts: weight neutral, weight inclusive, mindful eating, mindfulness-based interventions, size or body acceptance, and/or Health at Every Size® (HAES®).

Evidence is limited for non-dieting approaches. A systematic review and meta-analysis of nine studies (involving 1194 participants, BMI ≥ 25 kg/m² and follow-up over three–12 months) compared weight-neutral approaches to weight-loss interventions. Authors concluded that the two RCTs and seven non-randomized comparative studies found no significant differences in weight loss, BMI changes, cardio-metabolic outcomes (including blood pressure, glycemic control, lipid profile) or self-reported depression, self-esteem, QoL or diet quality. Small differences were found in self-reported bulimia and binge-eating behaviours.⁶¹ One systematic review examined the Health at Every Size approach. HAES® does not support the medicalization or pathological narrative that obesity is a disease. It's a philosophy centred on respecting body shape and size diversity, health, and promoting eating and exercise behaviours based on non-weight centric goals.¹⁴⁹ The review found this approach improved QoL and psychological outcomes (general well-being, body image perceptions) with mixed results for cardiovascular outcomes (blood lipids, blood pressure), body weight, physical activity, cognitive restraint and eating behaviours.⁵⁷

Another systematic review of randomized and non-randomized trials found various non-dieting approaches have evidence to positively influence eating behaviours (including disordered eating patterns), biochemical outcomes, fitness, diet quality, body image and mental health.^{57,150}

Mindfulness-based interventions targeting self-awareness, specifically hunger, satiety and taste satisfaction, have been found to be effective for binge eating behaviours,^{151–153} eating disorders,¹⁵¹ positively affecting eating behaviours¹⁴⁸ and weight loss.^{154,155} However, caution is needed when interpreting results from non-dieting approaches. There are various non-diet interventions reported in literature with a lack of control groups, a high risk of bias in trials, and inconsistent valid tools used to measure outcomes. Nonetheless, interventions focusing on non-weight loss or weight-neutral outcomes may have less impact on weight stigma and may support health behaviours across all weight spectrums, emphasizing the role non-dieting approaches could have on individualized nutrition interventions.

Clinical nutrition implications for acute weight-loss

In many clinical settings (primary care, acute or tertiary care, long-term care, etc.), some individuals living with obesity may benefit from acute weight loss. Acute weight loss can be desirable for the preservation of life, prevention of organ failure and/or for improving

functional QoL (i.e., compromised activities of daily living). Despite the risk for possible negative consequences of weight loss (i.e. weight gain, increased appetite, lean mass loss, etc.), acute weight loss via nutrition interventions may be a necessary and/or preferred treatment option as with other acute interventions. For example, someone with an ischemic bowel may require multiple bowel resections, resulting in parenteral nutrition support, intravenous vitamins/minerals, changes to macronutrient needs and lifelong monitoring of health, which may include monitoring weight for indicators of malnutrition. Likewise, someone with end-stage renal disease that requires renal replacement therapy may require medical nutrition therapy and food choice adjustment to maintain electrolytes, kidney function and organ preservation. Like obesity, nutrition interventions may be indicated for improvements in weight outcomes or cardiometabolic factors. Healthcare providers should use non-judgemental approaches when educating patients/clients about the benefits and risks of any nutrition intervention, including weight-loss interventions. Likewise, family members and/or the public should not judge or scrutinize individualized interventions indicated or selected by the patient/client and their healthcare provider.

Healthcare providers should practice caution, though, if using nutrition interventions for acute weight loss, as some individuals may be at high risk for malnutrition and/or sarcopenic obesity.^{156–159} For example, weight reduction for people with knee osteoarthritis is often recommended to reduce pain and decrease the risk of infection for surgery (rates are higher in patients with BMI >30 kg/m² after total knee replacement).¹⁶⁰ However, BMI is not a good indicator of health or body composition, and weight reduction may not improve risk or outcomes due to muscle weakness, muscle mass loss, or sarcopenic obesity or malnutrition due to inadequate oral intake.¹⁶⁰ Nutrition interventions therefore should be used for optimizing nutritional, medical and functional health rather than facilitating weight loss specific goals. Conducting a comprehensive assessment (as outlined in *the Assessment of People Living with Obesity* chapter) and collaborating with a registered dietitian is recommended for the safety and efficacy of using nutrition interventions in acute weight loss.

Other considerations

Micronutrient deficiencies

People living with obesity are at increased risk for micronutrient deficiencies including but not limited to vitamin D, vitamin B12 and iron. The prevalence of vitamin D deficiency in obesity has been reported to be as high as 90%,¹⁶¹ theorized by decreased bioavailability of vitamin D as it is sequestered in adipose tissue¹⁶² or due to volumetric dilution.¹⁶³ Systematic reviews and meta-analyses of randomized clinical trials indicate that higher adiposity levels (% fat mass or fat mass) is associated with lower serum vitamin D 25(OH) D levels,^{164–166} suggesting the need for healthcare providers to monitor vitamin D levels as part of routine assessment for obesity. Vitamin D supplementation has not been effective in treating obesity or for improving cardiometabol-

ic outcomes as shown by meta-analyses of randomized clinical trials.^{165,167,168} However, vitamin D supplementation for correction and/or prevention of deficiency (< 50 nmol/L as defined by the Institute of Medicine¹⁶⁹) is recommended, especially in individuals at higher risk for vitamin D deficiency (Table 3).

Restrictive eating patterns, obesity treatments (e.g. medications, bariatric surgery) and drug-nutrient interactions may also result in micronutrient deficiencies, specifically vitamin B12 and iron deficiencies.^{161,170,171} There is also growing evidence for thiamine (vitamin B1) and magnesium deficiencies.¹⁷² Vitamin B12 deficiency has been shown to be associated with higher BMI categories,¹⁷³ however, interpretation of observational studies is cautioned due to large heterogeneity within studies. Poor iron status has also been associated with obesity with a 1.31-fold increased risk for iron deficiency in people living with obesity.¹⁷⁰ Assessment including biochemical values can help inform recommendations for food intake, vitamin/mineral supplements, and possible drug-nutrient interactions (Table 3).

Disordered eating patterns

Healthcare providers may be hesitant to recommend restricting intake or VLCDs, as an early literature review found the development of eating disorders in college-aged women was associated with a history of intentional caloric restriction for weight loss.¹⁷⁴ Current evidence shows mixed results, however, as limited studies have specifically assessed whether “dieting” practices (for pursuit of an ideal body weight or shape, drive for thinness and goals of weight loss) precipitate eating disorders (such as binge eating disorder or disordered eating behaviours). Epidemiological data over a 20-year longitudinal study indicated that eating disorders, drive for thinness, use of diet pills, laxatives and dieting methods to control weight declined in adult women but increased for adult men.¹⁷⁵

A systematic review¹⁷⁶ found very low-calorie diets can be used without exacerbating existing eating disorders or binge eating episodes in medically supervised programs. Da Luz et al.¹⁷⁶ found binge eating decreased in VLCD interventions. A prospective randomized control trial found no disordered eating behaviours, no binge eating disorder and decreased symptoms of depression in calorically restricted groups (1200 kcal–1500 kcal/day with conventional food, or 1000 kcal/day with full meal replacements) when compared to a non-caloric restricted approach.¹⁷⁷ Symptoms of poor self-esteem and negative body image thoughts declined in all three groups over time. Furthermore, a review paper of cross-sectional and prospective studies on dietary restriction and the development of eating disorders or disordered eating behaviours confirmed minimal to no evidence to support the causation.¹⁷⁸ Caution is recommended when interpreting findings from this report, as study intentions were not designed to specifically investigate dieting and eating disorders or disordered eating behaviours in people living with obesity.

A recent systematic review by the Australian National Eating Disorder Collaboration concluded that professional obesity management

interventions (using medical nutrition therapy, physical activity, behaviour therapy, pharmacotherapy or surgical interventions) does not precipitate eating disorders or increase risk for eating disorders in people with BMI ≥ 25 kg/m².⁶³ However, eating disorders are often underdiagnosed and untreated, and some evidence suggesting that people with eating disorders are more likely to seek weight-loss interventions.⁶² Healthcare providers should consider referral to mental health professionals and/or eating disorder programs for assessment and treatment if symptoms are suspected. (Refer to the [Role of Mental Health in Obesity Management](#) chapter).

Assess risk for malnutrition prior to bariatric surgery

Limited high-quality evidence has reviewed preoperative malnutrition status in patients seeking bariatric surgery. Nonetheless, observational studies have indicated that patients living with obesity have a higher risk for inadequate nutritional status^{156,179,180} and malnutrition.¹⁵⁶⁻¹⁵⁸ A large, multicentre, retrospective, observational study (n=106,577) found that ~6% of patients undergoing bariatric surgery were malnourished and had increased risk of death or serious morbidity (DSM) and 30-day readmission rates.¹⁵⁷ This study also found that >10% weight loss prior to surgery was associated with nine times higher rates of death or serious disease conditions in patients with mild malnutrition and ten times higher death or serious disease conditions in those with severe malnutrition.³³ Similarly, a retrospective cohort study¹⁵⁸ concluded that 32% of the cohort (n= 533) had malnutrition prior to surgery. Higher BMI was associated with increased risk for malnutrition. Post-operative nausea and vomiting was associated with preoperative malnutrition. Preoperative evaluation and collaborative support from an RD are recommended for all patients considering bariatric surgery.^{161,181} Refer to the [Bariatric Surgery: Selection and Preoperative Work-up](#) chapter for further bariatric surgery considerations.

Limitations and opportunities

To support evidence-based practice, guideline chapter authors examined the literature to find the highest-quality evidence to inform graded recommendations. High-quality evidence was identified for specific nutrition-related topics including MNT delivered by an RD, specific dietary patterns, certain food-based approaches, and intensive behavioural therapy. There was limited evidence for non-dieting approaches. Gaps in the literature included assessment of baseline nutrition status and social determinants of health. Most studies with a nutrition component were short- to medium-term interventions, limiting our knowledge of long-term outcomes.

Studies using BMI >25 kg/m² as inclusion criteria to select participants for obesity interventions may be confounded with healthy people with larger bodies and misrepresent clinical outcomes for people with the chronic disease of obesity, and may not identify those at nutrition risk.

Weight loss was a common outcome measure of intervention studies; however, the reason for weight change is difficult to ascertain. The

success or failure of the intervention on weight outcomes is confounded by the physiological defense mechanisms in response to adiposity changes, as discussed in the [Science of Obesity](#) chapter.

To move nutrition and obesity practice forward, we suggest the following:

- Develop assessment tools for the primary care environment to support the use of a health-complication-centric definition of obesity, rather than relying on anthropometric measures for BMI categories.
- Improve accuracy of nutrition interventions for people with obesity with measurements of energy, macro/micronutrient needs and body composition.
- Nutrition is about more than the food we eat. Explore the relationships with food, food security, internalized weight bias, weight stigma and/or discrimination, eating behaviours and social determinants of health as part of patient care and research.
- Include the patient/client voice in nutrition research and patient care to help align the interventions for people living with obesity and people with larger bodies with their lived experiences.


Evidence continues to emerge that impacts our understanding of nutrition and chronic disease. Providers may look to enhance their professional knowledge on emerging evidence in nutrition-related topics, including:

- Neurophysiologic pathways that affect hunger, appetite and reward;
- Metabolic adaptation of caloric restriction;
- Gut microbiota;
- Nutrigenomics and personalized nutrition;
- Social determinants of health; and
- Mental health.

Conclusion

Nutrition interventions show benefits with cardiometabolic outcomes, including glycemic control, hypertension, lipid profile and cardiovascular risk (Table 1 and Figure 1). MNT and co-ordination of care with an RD can help patients/clients improve health and QoL. Finding a nutrition approach a patient/client can incorporate into their lives that is nutritionally adequate, culturally acceptable, affordable, enjoyable and effective for lifelong health improvements (Figure 2) should be the focus of all nutrition interventions.

Figure 1: Medical Nutrition Therapy for Obesity Management – Quick Reference Guide^{182,183}



*Refer to Table 2: Health Indicators for Evaluating Nutrition Interventions with Patients/Clients

Figure 2: Summary of Clinical Outcomes for Nutrition Interventions

	Hunger, satiety	Blood pressure	Blood lipids	Weight	Waist circumference	Body composition	CVD, CHD morbidity, mortality	Risk CVD	Glycemic control	Risk T2DM	Metabolic Syndrome	Quality of Life	Depression
Medical Nutritional Therapy (RD)	■	■	■	■	■				■				
Intensive behavioural therapy	NR	■	■	■			■		■		■		
Calorie restriction		■	■	■		■			■	■			
Lower carbohydrate				■									
Dietary fibre (25–29 mg)		■	■	■		■	■		■				
Low-calories sweeteners				■			■						
Higher protein (25–40%)	■		■	■		■							
Increased protein + calorie restriction			■	■		■							
Whey protein supplement		■	■	■		■			■				
Replace fat or carb with protein					■								
Lower fat				■									
Mediterranean			■				■		■	■	■		
Vegetarian			■	■			■		■	■			
Portfolio		■	■				■						
Low glycemic index			■	■			■			■			
DASH			■	■	■		■		■	■			
Meal replacements		■		■					■			■	
Intermittent fasting				■									
Pulses		■	■					■	■				
Vegetables and fruits		■					■		■	■			
Nuts			■				■		■				
Whole grains			■										
Dairy				■	■	■				■			
HAES®	■		■									■	■
Mindfulness-based approaches				■					■				

Table 1: Summary of Nutrition Interventions used in Obesity Management

Intervention	Outcomes/Impact		Advantages	Disadvantages
	Health and quality of life	Weight change		
Medical nutrition therapy by a registered dietitian (RD)	<ul style="list-style-type: none"> ↓ 0.43% HgA1c ↓ 2.16 cm waist circumference ↓ 4.06 mg/dL cholesterol ↓ 8.83 mg/dL triglycerides ↓ 4.43 mg/dL LDL-C ↓ 7.90 mmHg systolic blood pressure ↓ 2.60 mmHg DSP 	<ul style="list-style-type: none"> ↓ 1.03 kg⁶ For T2DM: ↓ 1.54 kg⁸ For T2DM prevention: ↓ 2.72 kg⁷ 	Use RDs as an adjunct or stand-alone therapy option for improvements in cardiometabolic and weight outcomes	Access to RDs trained in obesity management may be limited; fee for services from private practice providers
Intensive behavioural therapy	<ul style="list-style-type: none"> T2DM incidence 58%⁵¹ ↓ 0.22 A1c, ↓ 1.9 mmHg systolic blood pressure, ↑ 1.2 mg/dL HDL-C⁵⁰ ↓ Cardiovascular disease (HR 0.67) and all-cause mortality (HR 0.74)⁵² ↑ Remission of T2DM⁵³ ↓ Nephropathy incidence (HR 0.69)⁵⁴ ↓ Obstructive sleep apnea incidence⁵⁵ ↓ Depression (HR 0.85)⁵⁶ 	<ul style="list-style-type: none"> ↓ 8.6% 1 yr ↓ 6% 13.5 years⁵⁰ 	Multi-modal approach with intensive counselling and strategies provides support to individuals for longer-term behaviour change and successful outcomes	Requires significant resources across multiple healthcare disciplines
Dietary pattern approaches				
Calorie restriction*	<ul style="list-style-type: none"> ↓ Blood pressure, lipids, glucose^{69,184,185} ↓ Bone density⁷⁵ ↓ Muscle strength⁷⁶ ↓ BMR¹⁸⁶ 		Large initial weight loss ^{69,71,135,187}	Difficult to sustain, weight regain expected, long-term weight loss <5% ^{69,71,135,187}
Lower carbohydrate		↓ 8 kg at 6 mo; ↓ 6–7 kg at 1 year ⁹		
Dietary fibre (25 g to 29 g)	<ul style="list-style-type: none"> Higher intakes: ↓ Cardiovascular disease mortality 15–30% ↓ Coronary heart disease, stroke incidence ↓ T2DM ↓ Systolic blood pressure ↓ Total cholesterol⁹⁷ 	<ul style="list-style-type: none"> Higher intakes ↓ weight 	Fibre supplements may help ↓ weight short-term ^{108,188–192}	
Low-calorie sweeteners	May ↓ weight and cardiometabolic disease ^{118,193}		As a replacement for sugar (e.g. SSB) may help ↓ weight ¹²¹	Randomized control trials do not support use for obesity management ¹¹⁸
Higher protein (25%–40% of calories from protein), no calorie restriction prescribed	<ul style="list-style-type: none"> ↓ TG (-0.60 mmol/L)⁸⁰ Carb-to-protein ratio of 1.5:1 ↓ Chol, LDL¹⁹⁴ No change (with or without exercise) for HDL, FBG, fasting insulin¹⁹⁴ 	<ul style="list-style-type: none"> ↓ 0.39 kg BW ↓ 0.44 kg FM⁸⁰ 	<ul style="list-style-type: none"> Greater satiety¹⁹⁵ Women with MetSyn had ↓ weight, ↓ fat mass with HP vs. low-fat/high carb¹⁹⁴ 	No differences in other lipids or lean mass, attrition rates 30–40% ⁸⁰

Dietary pattern approaches

Increased protein (1.1 g/kg or 30% protein intake), with calorie restriction	Short-term (12 +- 9.3 weeks): ↓ TG ¹⁹⁵	30% protein intake: No difference in wt loss, ↑ lean mass ¹⁹⁶ ↓ Weight ¹⁹⁷ 1.1 g/kg protein intake: short-term (12 +- 9.3 weeks): ↓ Weight ↓ Fat mass Less ↓ fat-free mass, ¹⁹⁵	Greater satiety ¹⁹⁵	Short term (12 +- 9.3 weeks) ¹⁹⁵ Limited health data collected
Whey protein supplement (20–75 g/day, 2 weeks – 15 months)	↓ Cardiovascular disease risk factors (systolic blood pressure, DBP, HDL, TChol, glucose ⁹¹)	↓ Weight (mean diff -0.56 kg) ↓ Fat mass (mean diff -1.12 kg ⁹¹) ↓ Lean mass (mean diff -0.77 kg)	Benefits found with or without calorie restriction ⁹¹	Lack of evidence to guide dose or length of time for use ⁹¹
Increase protein to replace other macronutrients	Replace some carbohydrate ↓ Waist circumference over 5 years ¹⁹⁸ Replace some fat No effect ¹⁹⁸	No effect on long-term weight outcomes ¹⁹⁸		
Lower fat		↓ 8 kg at 6 mo; ↓ 6–7 kg at 1 yr ⁹		
Mediterranean	↓ A1C 0.45, ↓ TG 0.21 mmol/L, ↑ HDL-C 0.07 mmol/L ¹⁰ ↓ Cardiovascular events (HR 0.69–0.72) ¹¹ ↓ T2DM risk 52% ^{12,13} ↑ Reversion of MetSx ¹⁴	Little effect on weight or waist circumference ¹¹		
Vegetarian	↓ A1C 29%, ↓ LDL-C 0.12 mmol/L, ↑ non-HDL-C 0.13 mmol/L ¹⁶ ↓ T2DM incidence (OR 0.726) ¹⁷ ↓ Coronary heart disease incidence (RR 0.72) ↓ Coronary heart disease mortality (RR 0.78) ¹⁸	↓ 2.15 kg <6 mo ¹⁶		Risk of vitamin/ mineral deficiencies (iron, calcium, zinc, vitamin B12, vitamin D)
Portfolio	↓ LDL-C 17% ↓ Apo B 15% ↓ Non-HDL-C 14%, ↓ CRP 32%, ↓ systolic blood pressure 1%, ↓ 10-yr coronary heart disease risk 13% ¹⁹	No change		Individuals may find it difficult to meet the recommended food component targets**
Low-glycemic index	↑ HDL-C ¹⁹⁹ ↓ T2DM risk ²⁴ ↓ Coronary heart disease ²⁵	↓ 2.5 kg 18 months ²⁰⁰		
Dietary Approaches to Stop Hypertension (DASH)	↓ CRP 1.01 ²⁸ ↓ LDL-C 0.20 mmol/L ↓ A1C 0.53% ↓ T2DM risk RR 0.82 ↓ Cardiovascular disease risk RR 0.80 ↓ Coronary heart disease risk RR 0.79 ↓ Stroke risk RR 0.81 ²⁷	↓ 1.42 kg, ↓ waist circumference 1.05 cm in 24 weeks ²⁶		
Partial meal replacements*	↓ Blood glucose in DM ²⁰¹ ↑ HRQOL ²⁰² ↓ Systolic blood pressure 4.97 mmHg ↓ DBP 1.98 mmHg ↓ A1C 0.45% at 24 weeks ³⁴	↓ 2.37 kg ↓ Waist circumference 2.24 cm at 24 weeks ³⁴	Large initial wt loss	Wt regain 3 year weight loss < 5% ²⁰²
Intermittent fasting		↓ 0.61 kg at 24 weeks ³⁵		

Food-based approaches

Pulses	<ul style="list-style-type: none"> ↓ FBG 0.82³⁷ ↓ LDL-C 0.17 mmol/L³⁸ ↓ Systolic blood pressure 2.25 mmHg³⁹ ↓ Coronary heart disease risk RR 0.86⁴⁰ 	↓ 0.34 kg at 6 weeks ³⁶		
Vegetables and fruit	<ul style="list-style-type: none"> ↓ DBP 0.29 mmHg⁴¹ ↓ A1C 5.7%⁴² ↓ T2DM risk 42%⁴³ ↓ Cardiovascular mortality HR 0.95⁴⁴ 			
Nuts	<ul style="list-style-type: none"> ↓ A1C 0.07% ↓ FBG 0.15 mmol/L⁴⁵ ↓ LDL-C 7.4%⁴⁶ ↓ Coronary heart disease risk HR 0.74 			
Whole grains	<ul style="list-style-type: none"> ↓ total cholesterol (TC) 0.12 mmol/L ↓ LDL-C 0.09 mmol/L⁴⁸ 			
Dairy Foods (with calorie restriction)	<ul style="list-style-type: none"> ↓ T2DM risk 42%⁴³ 	<ul style="list-style-type: none"> ↓ 0.64 kg BW ↓ 2.18 cm waist circumference ↓ 0.56 kg FM ↑ 0.43 kg lean mass⁴⁹ 		

Non-dieting approaches

Health at Every Size (HAES [®])	<ul style="list-style-type: none"> ↓ LDL-C ↑ Body image perceptions ↑ Quality of life (QOL) scores (depression) ↑ Eating behaviour scores ↓ Hunger ↑ Aerobic activity 	No change in BMI or weight loss	↓ Weight bias	Evidence limited to women with BMI>25 or disordered eating patterns.
Mindful eating	<ul style="list-style-type: none"> ↓ 3.1 mg/dl (↓ 0.2 mmol/L) in blood glucose²⁰³ prevention of increasing FG over time 	<ul style="list-style-type: none"> ↓ 3.3% weight at post-treatment ↑ 3.5% weight in follow-up¹⁵⁴ ↓ 4.2–5.0 kg (4.3–5.1%) mean weight at 18 mo²⁰³ 	↓ Sweet food intake ²⁰⁴	Lack of consistency for validated mindfulness tools

LDL-C: low-density lipoprotein C; BMI: body mass index; FG: fasting glucose; TC: total cholesterol; HDL: high density lipoprotein; A1C; kg: kilogram; BW: body weight; FM: fat mass; T2DM: type 2 diabetes

*These are typically combined with extensive behavioural modification support.

** The Portfolio dietary pattern = 1g to 3g/day plant sterols (plant-sterol containing margarines, supplements), 15 g to 25 g/day viscous fibres (gel-forming fibres, such as from oats, barley, psyllium, legumes, eggplant, okra), 35–50 g/day plant-based protein (such as from soy and pulses) and 25 g to 50 g/day nuts (including tree nuts and peanuts).

Table 2: Health Indicators for Evaluating Nutrition Interventions with Patients/Clients

Health Improvement	Health indicator	Example
Cognitive improvements	Memory, concentration, attention, problem solving, sleep hygiene	Ask client/patient to rate each of these health outcomes using a 0–10 scale, where 0 is low/poor and 10 is high/great: Energy level Stress Sleep hygiene Mobility Strength Pain Bowel health Mood Relationship with food Hunger Cravings Overall health
Functional improvements	Strength, flexibility, mobility, coordination, physical activity capacity, endurance, pain	
Medical improvements	Cardiometabolic, endocrine, gastrointestinal, wound care, nutrient deficiencies, changes to medications	
Body composition improvements	Body fat, muscle mass, bone health, waist circumference	
Appetite-related improvements	Hunger, satiety, cravings, drive to eat, palatability of foods	
Mental health	Disordered eating behaviours, self-esteem, self-efficacy, emotional regulation, mood/anxiety, addiction	

Healthcare providers are encouraged to use health and quality of life (QoL)-related goals for evaluating effectiveness of nutrition interventions. Ask clients/patients what health improvements they are hoping to achieve by following or changing their nutrition approach helps to redirect weight-centric outcomes with asking

what health improvements this weight change means to them. Examples: energy level, cognitive improvements, functional improvements, cardiometabolic improvements, mental health and quality of life (mobility, self-hygiene, etc.),

Table 3: Micronutrients of Concern in Adults Living with Obesity

Micronutrient	Screen for Deficiency Risks	Drug or Nutrient Interactions
Vitamin D	<ol style="list-style-type: none"> 1. Elevated adiposity 2. Medical conditions associated with fat malabsorption: <ul style="list-style-type: none"> • Crohn's disease • Ulcerative colitis • Celiac disease • Liver disease • Cystic fibrosis • Short-bowel syndrome 3. Previous bariatric surgery (RYGB, SG, BPD, DS) 4. Low intake of calcium-rich foods 5. Limited sun-light exposure (i.e. Night-shift workers, wearing long-sleeved clothing, northern climate) 6. Darker skin pigmentation 	<ul style="list-style-type: none"> • Corticosteroids • Orlistat • Cholestyramine • Phenobarbital • Phenytoin
Vitamin B12	<ol style="list-style-type: none"> 1. Elevated adiposity 2. Medical conditions: <ul style="list-style-type: none"> • IBD (Crohn's disease, ulcerative colitis) • Type 2 diabetes (long-term use of metformin) • GERD • Positive Helicobacter pylori • Pernicious anaemia • Alcoholism 3. Restrictive eating patterns: <ul style="list-style-type: none"> • Vegetarian eating patterns • VLCD/meal replacements • Lower carbohydrate intake 4. Previous bariatric surgery (LAGB, RYGB, SG, BPD, DS) 	<ul style="list-style-type: none"> • Metformin • Proton-pump inhibitors
Iron	<ol style="list-style-type: none"> 1. Elevated adiposity 2. Medical conditions: <ul style="list-style-type: none"> • Crohn's disease • Ulcerative colitis • Celiac disease • Liver disease • Peptic ulcers • Chronic kidney disease 3. Restrictive eating patterns: <ul style="list-style-type: none"> • Vegetarian eating patterns • Low protein intake • VLCD/meal replacements 4. Frequent blood donors 5. Blood loss (menstruation, GI tract bleeding) 6. Previous bariatric surgery (LAGB, RYGB, SG, BPD, DS) 	<ul style="list-style-type: none"> • Interactions with calcium, polyphenols (coffee/tea) • Excessive zinc intake (lozenges) • NSAIDs • Proton-pump inhibitors • H2 blockers

Correspondence:
guidelines@obesitynetwork.ca

References

1. Puhl RM, Heuer CA. Obesity stigma: Important considerations for public health. *Am J Public Health*. 2010;100(6):1019-1028. doi:10.2105/AJPH.2009.159491
2. Brownell KD, Kersh R, Ludwig DS, et al. Personal responsibility and obesity: A constructive approach to a controversial issue. *Health Aff*. 2010;29(3):379-387. doi:10.1377/hlthaff.2009.0739
3. Salas XR, Forhan M, Caulfield T, Sharma AM, Raine KD. Addressing internalized weight bias and changing damaged social identities for people living with obesity. *Front Psychol*. 2019;10. doi:10.3389/fpsyg.2019.01409
4. Ralston J, Brinsden H, Buse K, et al. Time for a new obesity narrative. *Lancet*. 2018;392(10156):1384-1386. doi:10.1016/S0140-6736(18)32537-6
5. Koliaki C, Spinou T, Spinou M, Brinia M-E, Mitsopoulou D, Katsilambros N. Defining the Optimal Dietary Approach for Safe, Effective and Sustainable Weight Loss in Overweight and Obese Adults. *Healthcare*. 2018;6(3). doi:10.3390/healthcare6030073
6. Williams L, Barnes K, Ball L, Ross L, Sladdin I, Mitchell L. How Effective Are Dietitians in Weight Management? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Healthcare*. 2019;7(1):20. doi:10.3390/healthcare7010020
7. Raynor HA, Davidson PG, Burns H, et al. Medical Nutrition Therapy and Weight Loss Questions for the Evidence Analysis Library Prevention of Type 2 Diabetes Project: Systematic Reviews. *J Acad Nutr Diet*. 2018;117(10):1578-1611. doi:10.1016/j.jand.2017.06.361
8. Razaz JM, Rahmani J, Varkaneh HK, Thompson J, Clark C, Abdulazeem HM. The health effects of medical nutrition therapy by dietitians in patients with diabetes : A systematic review and meta- analysis : Nutrition therapy and diabetes. *Prim Care Diabetes*. 2019.
9. Johnston BC, Kanters S, Bandayrel K, et al. Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults A Meta-analysis. *JAMA*. 2014;312(9):923-933. doi:10.1001/jama.2014.10397
10. Pan B, Wu Y, Yang Q, et al. The impact of major dietary patterns on glycemic control, cardiovascular risk factors, and weight loss in patients with type 2 diabetes : A network meta-analysis. *J Evid Based Med*. 2019;12(1):29-39. doi:10.1111/jebm.12312
11. Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. *N Engl J Med*. 2018;378(25):e34.
12. Salas-Salvadó J, Bulló M, Babio N, Martínez-González M, Ibarrola-Jurado N, Basora J. Reduction in the Incidence of Type 2 Diabetes With the Mediterranean Diet Results of the PREDIMED-Reus nutrition intervention randomized trial. *Diabetes Care*. 2011;34(1):14-19. doi:10.2337/dc10-1288.
13. Salas-Salvadó J, Bulló M, Babio N, et al. Erratum. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. *Diabetes Care*. 2011;41(10):2259-2260.
14. Babio N, Toledo E, Estruch R, et al. Mediterranean diets and metabolic syndrome status in the PREDIMED randomized trial. *CMAJ*. 2014;186(17):E649-E657.
15. The Editors of The Lancet Diabetes Endocrinology. Retraction and republication-Effect of a high-fat Mediterranean diet on bodyweight and waist circumference: a prespecified secondary outcomes analysis of the PREDIMED randomised controlled trial. *Lancet Diabetes Endocrinol*. 2019;7(5):334. doi:10.1016/S2213-8587(19)30073-7.Retraction
16. Viguioliouk E, Kendall CW, Kahleová H, et al. Effect of vegetarian dietary patterns on cardiometabolic risk factors in diabetes : A systematic review and meta-analysis of randomized controlled trials. *Clin Nutr*. 2019;38(3):1133-1145. doi:10.1016/j.clnu.2018.05.032
17. Lee Y, Park K. Adherence to a Vegetarian Diet and Diabetes Risk : A Systematic Review and Meta-Analysis of Observational Studies. *Nutrients*. 2017;9(6):603. doi:10.3390/nu9060603
18. Glenn AJ, Viguioliouk E, Seider M, et al. Relation of Vegetarian Dietary Patterns With Major Cardiovascular Outcomes : A Systematic Review and Meta-Analysis of Prospective Cohort Studies. *Front Nutr*. 2019;6:80. doi:10.3389/fnut.2019.00080
19. Chiavaroli L, Nishi SK, Khan TA, et al. Portfolio Dietary Pattern and Cardiovascular Disease: A Systematic Review and Meta-analysis of Controlled Trials. *Prog Cardiovasc Dis*. 2018;61(1):43-53. doi:10.1016/j.pcad.2018.05.004
20. Chiavaroli L, Kendall CWC, Braunstein CR, Mejia SB, Leiter LA, Jenkins DJA. Effect of pasta in the context of low- glycaemic index dietary patterns on body weight and markers of adiposity : a systematic review and meta-analysis of randomised controlled trials in adults. *BMJ Open*. 2018;8(3):e019438. doi:10.1136/bmjopen-2017-019438
21. Wang Q, Xia W, Zhao Z, Zhang H. Effects comparison between low glycemic index diets and high glycemic index diets on HbA1c and fructosamine for patients with diabetes : A systematic review and meta- analysis. *Prim Care Diabetes*. 2015;9(5):362-369.
22. Goff LM, Cowland DE, Hooper L, S FG. Low glycaemic index diets and blood lipids : a systematic review and meta-analysis of randomised controlled trials. *Nutr Metab Cardiovasc Dis*. 2013;23(1):1-10. doi:10.1016/j.numecd.2012.06.002.
23. Evans CEL, Greenwood DC, Threapleton DE, Gale CP, Cleghorn CL, Burley VJ. Glycemic index, glycemic load, and blood pressure : a systematic review and meta-analysis of randomized controlled trials. *Am J Clin Nutr*. 2017;105(5):1176-1190. doi:10.3945/ajcn.116.143685.One-third
24. Livesey G, Taylor R, Livesey HF, et al. Dietary Glycemic Index and Load and the Risk of Type 2 Diabetes : A Systematic Review and Updated Meta-Analyses of Prospective Cohort Studies. *Nutrients*. 2019;11(6):1280.
25. Livesey G, Livesey H. Coronary Heart Disease and Dietary Carbohydrate, Glycemic Index, and Glycemic Load: Dose-Response Meta-analyses of Prospective Cohort Studies. *Mayo Clin Proc Innov Qual Outcomes*. 2019;3(1):52-69. doi:10.1016/j.mayocpiqo.2018.12.007

26. Soltani S, Shirani F, Chitsazi MJ, Salehi-Abargouei A. The effect of dietary approaches to stop hypertension (DASH) diet on weight and body composition in adults : a systematic review and meta - analysis of randomized controlled clinical trials. *Obes Rev.* 2016;17(5):442-454.
27. Chiavaroli L, Vigiouliou E, Nishi SK, et al. DASH Dietary Pattern and Cardiometabolic Outcomes : An Umbrella Review of Systematic Reviews and Meta-Analyses. *Nutrients.* 2019;11(2):338. doi:10.3390/nu11020338
28. Soltani S, Chitsazi MJ, Salehi-Abargouei A. The effect of dietary approaches to stop hypertension (DASH) on serum inflammatory markers : A systematic review and meta-analysis of randomized trials. *Clin Nutr.* 2018;37(2):542-550.
29. Poulsen SK, Due A, Jordy AB, et al. Health effect of the New Nordic Diet in adults with increased waist circumference : a 6-mo randomized controlled trial. *Am J Clin Nutr.* 2014;99(1):35-45. doi:10.3945/ajcn.113.069393. INTRODUCTION
30. Poulsen SK, Crone C, Astrup A, Larsen TM. Long-term adherence to the New Nordic Diet and the effects on body weight, anthropometry and blood pressure : a 12- month follow-up study. *Eur J Nutr.* 2015;54(1):67-76.
31. Adamsson V, Reumark A, Fredriksson I, Hammarström E, Vessby B, Johansson G. Effects of a healthy Nordic diet on cardiovascular risk factors in hypercholesterolaemic subjects: a randomized controlled trial (NORDIET). *J Intern Med.* 2010;269(2):150-159. doi:10.1111/j.1365-2796.2010.02290.x
32. Uusitupa M, Hermansen K, Savolainen MJ, et al. Effects of an isocaloric healthy Nordic diet on insulin sensitivity, lipid profile and inflammation markers in metabolic syndrome – a randomized study (SYSDIET). *J Intern Med.* 2013;274(1):52-66. doi:10.1111/joim.12044
33. Lemming EW, Byberg L, Wolk A, Michaëlsson K. A comparison between two healthy diet scores, the modi fi ed Mediterranean diet score and the Healthy Nordic Food Index, in relation to all-cause and cause-specific mortality. *Br J Nutr.* 2018;119(7):836-846. doi:10.1017/S0007114518000387
34. Noronha JC, Nishi SK, Braunstein CR, et al. The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight / Obese Individuals With Type 2 Diabetes : A Systematic Review and Meta- analysis of Randomized Controlled Trials. *Diabetes Care.* 2019;42(5):767-776.
35. Cioffi I, Evangelista A, Ponzio V, et al. Intermittent versus continuous energy restriction on weight loss and cardiometabolic outcomes : a systematic review and meta - analysis of randomized controlled trials. *J Transl Med.* 2018;16(1):371. doi:10.1186/s12967-018-1748-4
36. Kim SJ, Souza RJ De, Choo VL, et al. Effects of dietary pulse consumption on body weight : a systematic review and meta-analysis of randomized controlled trials. *Am J Clin Nutr.* 2016;103(5):1213-1223. doi:10.3945/ajcn.115.124677.1
37. Sievenpiper JL, Kendall CWC, Esfahani A. Effect of non-oil-seed pulses on glycaemic control : a systematic review and meta-analysis of randomised controlled experimental trials in people with and without diabetes. *Diabetologia.* 2009;52(8):1479-1495. doi:10.1007/s00125-009-1395-7
38. Ha V, Sievenpiper JL, De Souza RJ, et al. Effect of dietary pulse intake on established therapeutic lipid targets for cardiovascular risk reduction : a systematic review and meta-analysis of randomized controlled trials. *Cmaj.* 2014;186(8):E252-E262.
39. Jayalath VH, Souza RJ De, Sievenpiper JL, et al. Effect of Dietary Pulses on Blood Pressure : A Systematic Review and Meta-analysis of Controlled Feeding Trials. *Am J Hypertens.* 2013;27(1):56-64. doi:10.1093/ajh/hpt155
40. Vigiouliou E, Mejia SB, Kendall CW, Sievenpiper JL. Can pulses play a role in improving cardiometabolic health? Evidence from systematic reviews and meta - analyses. *Ann N Y Acad Sci.* 2017;1392(1):43.
41. Shin JY, Kim JY, Kang HT, Han KH, Shim JY. Effect of fruits and vegetables on metabolic syndrome : a systematic review and meta- analysis of randomized controlled trials. *Int J Food Sci Nutr.* 2015;66(4):416-425.
42. Moazzen S, Amani R, Homayouni A, Shahbazian H. Effects of Freeze-Dried Strawberry Supplementation on Metabolic Biomarkers of Atherosclerosis in Subjects with Type Diabetes : A Randomized Double-Blind Controlled. *Ann Nutr Metab.* 2013;63(3):256-264. doi:10.1159/000356053
43. Schwingshackl L, Hoffmann G, Lampousi A-M, Knüppel S, Iqbal K, Schwedhelm C. Food groups and risk of type 2 diabetes mellitus : a systematic review and meta-analysis of prospective studies. *Eur J Epidemiol.* 2017;32(5):363-375. doi:10.1007/s10654-017-0246-y
44. Wang X, Ouyang Y, Liu J, Zhu M, Zhao G, Bao W. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: Systematic review and dose-response meta-analysis of prospective cohort studies. *BMJ.* 2014;349:g4490. doi:10.1136/bmj.g5472
45. Vigiouliou E, Kendall CWC, Mejia SB, et al. Effect of tree nuts on glycemic control in diabetes: A systematic review and meta-analysis of randomized controlled dietary trials. *PLoS One.* 2014;9(7):e103376. doi:10.1371/journal.pone.0103376
46. Sabaté J, Oda K, Ros E. Nut consumption and blood lipid levels : a pooled analysis of 25 intervention trials. *Arch Intern Med.* 2010;170(9):821-827. doi:10.1001/archinternmed.2010.79.Nut
47. Bao Y, Han J, Hu FB, et al. Association of nut consumption with total and cause-specific mortality. *N Engl J Med.* 2013;369(21):2001-2011. doi:10.1056/NEJMoa1307352
48. Holländer PLB, Ross AB, Kristensen M. Whole-grain and blood lipid changes in apparently healthy adults: A systematic review and meta-analysis of randomized controlled studies. *Am J Clin Nutr.* 2015;102(3):556-572. doi:10.3945/ajcn.115.109165
49. Geng T, Qi L, Huang T. Effects of Dairy Products Consumption on Body Weight and Body Composition Among Adults: An Updated Meta-Analysis of 37 Randomized Control Trials. *Mol Nutr Food Res.* 2018;62(1). doi:10.1002/mnfr.201700410
50. Wing R, Bolin P, Brancati F, Bray G, Clark J. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. *N Engl J Med.* 2013;369(2):145-154. doi:10.1007/s11883-014-0457-6
51. Knowler W, Barrett-Connor E, Fowler S, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med.* 2002;346(6):393-403.
52. Gong Q, Zhang P, Wang J, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. *Lancet Diabetes Endocrinol.* 2019;7(6):452-461. doi:10.1016/S2213-8587(19)30093-2
53. Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. *Lancet Diabetes Endocrinol.* 2019;7(5):344-355. doi:10.1016/S2213-8587(19)30068-3
54. Look AHEAD Research Group. Effect of a Long-Term Behavioral Weight Loss Intervention on Nephropathy in Overweight or Obese Adults with Type 2 Diabetes: the Look AHEAD Randoized Clinical Trial. *Lancet Diabetes Endocrinol.* 2014;2(10):801-809. doi:10.1016/S2213-8587(14)70156-1.Effect
55. Kuna ST, Reboussin DM, Borradaile KE, et al. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. *Arch Intern Med.* 2013;36(5):641-649. doi:10.1001/archinternmed.2009.266
56. Rubin R, Wadden T, Bahnson J, Blackburn G, Brancati F, Bray G. Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: The look AHEAD trial. *Diabetes Care.* 2014;37(6):1544-1553. doi:10.2337/dc13-1928
57. Ulian MD, Aburad L, da Silva Oliveira MS, et al. Effects of health at every size® interventions on health-related outcomes of people with overweight and obesity: a systematic review. *Obes Rev.* 2018;19(12):1659-1666. doi:10.1111/obr.12749
58. Raynor HA, Champagne CM. Position of the Academy of Nutrition and Dietetics: Interventions for the Treatment of Overweight and Obesity in Adults. *J Acad Nutr Diet.* 2016;116(1):129-147. doi:10.1016/j.jand.2015.10.031
59. Cho Y, Hong N, Kim K, Cho S, Lee M. The effectiveness of intermittent fasting to reduce body mass index and glucose metabolism: A systematic review and meta-analysis. *J Clin Med.* 2019;8(10):1645.

60. Welton S, Minty R, Willms H, Poirier D, Madden S, Kelly L. Intermittent fasting and weight loss: Systematic review. *Can Fam Physician*. 2020;66(2):117-125.
61. Dugmore JA, Winten CG, Niven HE, Bauer J. Effects of weight-neutral approaches compared with traditional weight-loss approaches on behavioral, physical, and psychological health outcomes: a systematic review and meta-analysis. *Nutr Rev*. 2020;78(1):39-55. doi:10.1093/nutrit/nuz020
62. Hart LM, Granillo MT, Jorm AF, Paxton SJ. Unmet need for treatment in the eating disorders: A systematic review of eating disorder specific treatment seeking among community cases. *Clin Psychol Rev*. 2011;31(5):727-735. doi:10.1016/j.cpr.2011.03.004
63. National Eating Disorders Collaboration (NEDC). Eating Disorders & Obesity Treatments A systematic review of the physical, psychological and eating disorders outcomes from obesity treatments. Commonwealth Department of Health, Australia. Available from: <https://www.nedc.com.au/research-and-resources/show/eating-disorders-and-obesity-treatments> (Accessed: May 12, 2020).
64. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. *N Engl J Med*. 2011;365(17):1597-1604. doi:10.1056/NEJMoa1105816
65. Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. *Am J Clin Nutr*. 2008;88(4):906-912. doi:10.1093/ajcn/88.4.906
66. Hall KD, Heymsfield SB, Kemnitz JW, Klein S, Schoeller DA, Speakman JR. Energy balance and its components: Implications for body weight regulation. *Am J Clin Nutr*. 2012;95(4):989-994. doi:10.3945/ajcn.112.036350
67. American Diabetes Association. 5. Lifestyle management: Standards of medical care in diabetesd-2019. *Diabetes Care*. 2019;42(Supplement 1):S46-S60. doi:10.2337/dc19-S005
68. Bray GA, Heisel WE, Afshin A, et al. The science of obesity management: An endocrine society scientific statement. *Endocr Rev*. 2018;39(2):79-132. doi:10.1210/er.2017-00253
69. Nackers LM, Middleton KR, Dubyak PJ, Daniels MJ, Anton SD, Perri MG. Effects of prescribing 1,000 versus 1,500 kilocalories per day in the behavioral treatment of obesity: A randomized trial. *Obesity*. 2013;21(12):2481-2487. doi:10.1002/oby.20439
70. Ard JD, Gower B, Hunter G, et al. Effects of Calorie Restriction in Obese Older Adults: The CROSSROADS Randomized Controlled Trial. *Journals Gerontol Ser A*. 2017;73(1):73-80. doi:10.1093/gerona/glw237
71. Parretti HM, Jebb SA, Johns DJ, Lewis AL, Christian-Brown AM, Aveyard P. Clinical effectiveness of very-low-energy diets in the management of weight loss: A systematic review and meta-analysis of randomized controlled trials. *Obes Rev*. 2016;17(3):225-234. doi:10.1111/obr.12366
72. Thomas DM, Martin CK, Lettieri S, et al. Can a weight loss of one pound a week be achieved with a 3500-kcal deficit? Commentary on a commonly accepted rule. *Int J Obes*. 2013;37(12):1611-1613. doi:10.1038/ijo.2013.51
73. Hall KD, Chow CC. Why is the 3500 kcal per pound weight loss rule wrong? *Int J Obes*. 2013;37(12):1614. doi:10.1038/ijo.2013.112
74. Polidori D, Sanghvi A, Seeley RJ, Hall KD. How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake. *Obesity*. 2016;24(11):2289-2295. doi:10.1002/oby.21653
75. Zibellini J, Seimon R V., Lee CM, et al. Does Diet-Induced Weight Loss Lead to Bone Loss in Overweight or Obese Adults? A Systematic Review and Meta-Analysis of Clinical Trials. *J Bone Miner Res*. 2015;30(12):2168-2178. doi:10.1002/jbmr.2564
76. Zibellini J, Seimon R V., Lee CMY, Gibson AA, Hsu MSH, Sainsbury A. Effect of diet-induced weight loss on muscle strength in adults with overweight or obesity – a systematic review and meta-analysis of clinical trials. *Obes Rev*. 2016;17(8):647-663. doi:10.1111/obr.12422
77. Trumbo P, Schlicker S, Yates AA, Poos M. Food and Nutrition Board of the Institute of Medicine, The National Academies. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. *J Am Diet Assoc*. 2002;102(11):1621-1630. doi:10.1016/S0002-8223(02)90346-9
78. Gardner CD, Trepanowski JF, Gobbo LCD, et al. Effect of low-fat VS low-carbohydrate diet on 12-month weight loss in overweight adults and the association with genotype pattern or insulin secretion the DIETFITS randomized clinical trial. *JAMA - J Am Med Assoc*. 2018;319(7):667-679. doi:10.1001/jama.2018.0245
79. Korsmo-Haugen HK, Brurberg KG, Mann J, Aas AM. Carbohydrate quantity in the dietary management of type 2 diabetes: A systematic review and meta-analysis. *Diabetes, Obes Metab*. 2019;21(1):15-27. doi:10.1111/dom.13499
80. Clifton PM, Condo D, Keogh JB. Long term weight maintenance after advice to consume low carbohydrate, higher protein diets - A systematic review and meta analysis. *Nutr Metab Cardiovasc Dis*. 2014;24(3):224-235. doi:10.1016/j.numecd.2013.11.006
81. Mansoor N, Vinknes KJ, Veierod MB, Retterstol K. Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors a meta-analysis of randomised controlled trials. *Br J Nutr*. 2016;115(3):466-479. doi:10.1017/S0007114515004699
82. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. *N Engl J Med*. 2009;360(9):859-873. doi:10.1097/01.ogx.0000351673.32059.13
83. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone Diets for weight loss and heart disease risk reduction: A randomized trial. *J Am Med Assoc*. 2005;293(1):43-53. doi:10.1001/jama.293.1.43
84. Seidemann SB, Claggett B, Cheng S, et al. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. *Lancet Public Heal*. 2018;3(9):e419-e428. doi:10.1016/S2468-2667(18)30135-X
85. Dehghan M, Mente A, Zhang X, et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. *Lancet*. 2017;390(10107):2050-2062. doi:10.1016/S0140-6736(17)32252-3
86. Jenkins DJ, Wong JM, Kendall CW, et al. The effect of a plant-based low-carbohydrate ('Eco-Atkins') diet on body weight and blood lipid concentrations in hyperlipidemic subjects. *Arch Intern Med*. 2009;169(11):1046-1054. doi:10.1001/archinternmed.2009.257
87. Jenkins DJA, Wong JMW, Kendall CWC, et al. Effect of a 6-month vegan low-carbohydrate ('Eco-Atkins') diet on cardiovascular risk factors and body weight in hyperlipidaemic adults: A randomised controlled trial. *BMJ Open*. 2014;4(2):e003505. doi:10.1136/bmjopen-2013-003505
88. Qian F, Korat AA, Malik V, Hu FB. Metabolic effects of monounsaturated fatty acid-enriched diets compared with carbohydrate or polyunsaturated fatty acid-enriched diets in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. *Diabetes Care*. 2016;39(8):1448-1457. doi:10.2337/dc16-0513
89. Vigiouk E, Stewart SE, Jayalath VH, et al. Effect of replacing animal protein with plant protein on glycemic control in diabetes: A systematic review and meta-analysis of randomized controlled trials. *Nutrients*. 2015;7(12):9804-9824. doi:10.3390/nu7125509
90. Li SS, Mejia SB, Lytvyn L, et al. Effect of plant protein on blood lipids: A systematic review and meta-analysis of randomized controlled trials. *J Am Heart Assoc*. 2017;6(12):e006659. doi:10.1161/JAHA.117.006659
91. Wirunsawanya K, Upala S, Jaruvongvanich V, Sanguankeo A. Whey Protein Supplementation Improves Body Composition and Cardiovascular Risk Factors in Overweight and Obese Patients: A Systematic Review and Meta-Analysis. *J Am Coll Nutr*. 2018;37(1):60-70. doi:10.1080/07315724.2017.1344591
92. Hooper L, Martin N, Abdelhamid A, Davey Smith G. Reduction in saturated fat intake for cardiovascular disease. *Cochrane Database Syst Rev*. 2015;(6). doi:10.1002/14651858.CD011737
93. Ramsden CE, Zamora D, Leelarthaepin B, et al. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: Evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. *BMJ*. 2013;346:e8707. doi:10.1136/bmj.e8707

94. Li Y, Hruby A, Bernstein AM, et al. Saturated Fats Compared with Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of Coronary Heart Disease A Prospective Cohort Study. *J Am Coll Cardiol*. 2015;66(14):1538-1548. doi:10.1016/j.jacc.2015.07.055
95. Jakobsen MU, Dethlefsen C, Joensen AM, et al. Intake of carbohydrates compared with intake of saturated fatty acids and risk of myocardial infarction: Importance of the glycemic index. *Am J Clin Nutr*. 2010;91(6):1764-1768. doi:10.3945/ajcn.2009.29099
96. Miller V, Mente A, Dehghan M, et al. Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study. *Lancet*. 2017;390(10107):2037-2049. doi:10.1016/S0140-6736(17)32253-5
97. Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. *Lancet*. 2019;393(10170):434-445. doi:10.1016/S0140-6736(18)31809-9
98. Threapleton DE, Greenwood DC, Evans CEL, et al. Dietary fibre intake and risk of cardiovascular disease: Systematic review and meta-analysis. *BMJ*. 2013;347:f6879. doi:10.1136/bmj.f6879
99. Government of Canada. Summary of Health Canada's Assessment of a Health Claim about Food Products Containing Psyllium and Blood Cholesterol Lowering. Available from: <https://www.canada.ca/en/health-canada/services/food-nutrition/food-labelling/health-claims/assessments/psyllium-products-blood-cholesterol-lowering-nutrition-health-claims-food-labelling.html>.
100. Government of Canada. Summary of Health Canada's Assessment of a Health Claim about Barley Products and Blood Cholesterol Lowering. Available from: <https://www.canada.ca/en/health-canada/services/food-nutrition/food-labelling/health-claims/assessments/psyllium-products-blood-cholesterol-lowering-nutrition-health-claims-food-labelling.html>.
101. Government of Canada. Oat Products and Blood Cholesterol Lowering: Summary of Assessment of a Health Claim about Oat Products and Blood Cholesterol Lowering. Available from: <https://www.canada.ca/en/health-canada/services/food-nutrition/food-labelling/health-claims/assessments/products-blood-cholesterol-lowering-summary-assessment-health-claim-about-products-blood-cholesterol-lowering.html>. <http://www.hc-sc.gc.ca/fn-an/label-etiquet/claims-reclam/assess-evalu/oat-avoine-eng.php>. Published 2010.
102. Government of Canada. Summary of Health Canada's Assessment of a Health Claim about a Polysaccharide Complex (Glucomannan, Xanthan Gum, Sodium Alginate) and a Reduction of the Post-Prandial Blood Glucose Response. Available from: <https://www.canada.ca/en/health-canada/services/food-nutrition/food-labelling/health-claims/assessments/summary-assessment-health-claim-about-polysaccharide-complex-glucomannan-xanthan-sodium-alginate-reduction-post-prandial-blood-glucose>.
103. Jovanovski E, Khayat R, Zurbau A, et al. Should Viscous Fiber Supplements Be Considered in Diabetes Control? Results from a Systematic Review and Meta-analysis of Randomized Controlled Trials. *Diabetes Care*. 2019;42(5):755-766. doi:10.2337/dc18-1126
104. Jovanovski E, Yashpal S, Komishon A, et al. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: A systematic review and meta-analysis of randomized controlled trials. *Am J Clin Nutr*. 2018;108(5):922-932. doi:10.1093/ajcn/nqy115
105. Khan K, Jovanovski E, Ho HVT, et al. The effect of viscous soluble fiber on blood pressure: A systematic review and meta-analysis of randomized controlled trials. *Nutr Metab Cardiovasc Dis*. 2018;28(1):3-13. doi:10.1016/j.numecd.2017.09.007
106. Ho HVT, Jovanovski E, Zurbau A, et al. A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B. *Am J Clin Nutr*. 2017;105(5):1239-1247. doi:10.3945/ajcn.116.142158
107. Ho HVT, Sievenpiper JL, Zurbau A, et al. The effect of oat β -glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: A systematic review and meta-analysis of randomised-controlled trials. *Br J Nutr*. 2016;116(8):1369-1382. doi:10.1017/S000711451600341X
108. Chew KY, Brownlee IA. The impact of supplementation with dietary fibers on weight loss: A systematic review of randomised controlled trials. *Bioact Carbohydrates Diet Fibre*. 2018;14:9-19. doi:10.1016/j.bcdf.2017.07.010
109. Vuksan V, Jenkins AL, Jenkins DJA, Rogovik AL, Sievenpiper JL, Jovanovski E. Using cereal to increase dietary fiber intake to the recommended level and the effect of fiber on bowel function in healthy persons consuming North American diets. *Am J Clin Nutr*. 2008;88(5):1256-1262. doi:10.3945/ajcn.2008.25956.1
110. Vuksan V, Sievenpiper JL, Owen R, et al. Beneficial Effects of Viscous Dietary Fiber From Konjac-Mannan in Subjects Results of a controlled metabolic trial. *Diabetes Care*. 2000;23(1):9-14.
111. Vuksan V, Jenkins DJA, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes: A randomized controlled metabolic trial. *Diabetes Care*. 1999;22(6):913-919. doi:10.2337/diacare.22.6.913
112. Jenkins DJA, Kendall CWC, Augustin LSA, et al. Effect of legumes as part of a low glycemic index diet on glycemic control and cardiovascular risk factors in type 2 diabetes mellitus: A randomized controlled trial. *Arch Intern Med*. 2012;172(21):1653-1660. doi:10.1001/2013.jamainternmed.70
113. Jenkins DJA, Kendall CWC, Augustin LSA, et al. Effect of wheat bran on glycemic control and risk factors for cardiovascular disease in type 2 diabetes. *Diabetes Care*. 2002;25(9):1522-1528. doi:10.2337/diacare.25.9.1522
114. Anderson JW, Randles KM, Kendall CWC, Jenkins DJA. Carbohydrate and Fiber Recommendations for Individuals with Diabetes: A Quantitative Assessment and Meta-Analysis of the Evidence. *J Am Coll Nutr*. 2004;23(1):5-17. doi:10.1080/07315724.2004.10719338
115. Sievenpiper JL, Khan TA, Ha V, Viguioliouk E, Auyeung R. The importance of study design in the assessment of nonnutritive sweeteners and cardiometabolic health. *CMAJ*. 2017;189(46):E1424-5. doi:10.1503/cmaj.733381
116. Malik VS, Li Y, Pan A, et al. Long-Term Consumption of Sugar-Sweetened and Artificially Sweetened Beverages and Risk of Mortality in US Adults. *Circulation*. 2019;139(18):2113-2125. doi:10.1161/CIRCULATIONAHA.118.037401
117. Khan TA, Malik VS, Sievenpiper JL. Letter by Khan et al Regarding Article, "Artificially Sweetened Beverages and Stroke, Coronary Heart Disease, and All-Cause Mortality in the Women's Health Initiative." *Stroke*. 2019;50(6):E167-E168. doi:10.1161/STROKEAHA.119.025571
118. Azad MB, Abou-Setta AM, Chauhan BF, et al. Nonnutritive sweeteners and cardiometabolic health: A systematic review and meta-analysis of randomized controlled trials and prospective cohort studies. *CMAJ*. 2017;189(28):E929-E939. doi:10.1503/cmaj.161390
119. Toews I, Lohner S, Küllenberg De Gaudry D, Sommer H, Meerpohl JJ. Association between intake of non-sugar sweeteners and health outcomes: Systematic review and meta-analyses of randomised and non-randomised controlled trials and observational studies. *BMJ*. 2019;364. doi:10.1136/bmj.k4718
120. Peters JC, Beck J, Cardel M, et al. The effects of water and non-nutritive sweetened beverages on weight loss and weight maintenance: A randomized clinical trial. *Obesity*. 2016;24(2):297-304. doi:10.1002/oby.21327
121. Rogers PJ, Hogenkamp PS, De Graaf C, et al. Does low-energy sweetener consumption affect energy intake and body weight? A systematic review, including meta-analyses, of the evidence from human and animal studies. *Int J Obes*. 2016;40(3):381-394. doi:10.1038/ijo.2015.177
122. Maersk M, Belza A, Stødkilde-Jørgensen H, et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: A 6-mo randomized intervention study. *Am J Clin Nutr*. 2012;95(2):283-289. doi:10.3945/ajcn.111.022533
123. Raben A, Vasilaras TH, Møller AC, Astrup A. Sucrose compared with artificial sweeteners: different effects on ad libitum food intake and body weight after 10 wk of supplementation in overweight subjects. *Am J Clin Nutr*. 2002;76(4):721-729. doi:10.1186/1550-2783-4-8
124. Smith JD, Hou T, Hu FB, et al. A Comparison of Different Methods for Evaluating Diet, Physical Activity, and Long-Term Weight Gain in 3 Prospective Cohort Studies. *J Nutr*. 2015;145(11):2527-2534. doi:10.3945/jn.115.214171

125. Pan A, Malik VS, Schulze MB, Manson JE, Willett WC, Hu FB. Plain-water intake and risk of type 2 diabetes in young and middle-aged women. *Am J Clin Nutr*. 2012;95(6):1454-1460. doi:10.3945/ajcn.111.032698.1
126. Estruch R, Martínez-González MA, Corella D, et al. Effect of a high-fat Mediterranean diet on bodyweight and waist circumference: a prespecified secondary outcomes analysis of the PREDIMED randomised controlled trial. *Lancet Diabetes Endocrinol*. 2016;4(8):666-676. doi:10.1016/S2213-8587(16)30085-7
127. Viguioliouk E, Nishi SK, Wolever TMS, Sievenpiper JL. Point: Glycemic index'an important but oft misunderstood marker of carbohydrate quality. *Cereal Foods World*. 2018;63(4):158-164. doi:10.1094/CFW-63-4-0158
128. Thomas D, Elliott EJ, Baur L. Low glycaemic index or low glycaemic load diets for overweight and obesity. *Cochrane Database Syst Rev*. 2007;18(3). doi:10.1002/14651858.CD006296.pub2
129. Livesey G, Taylor R, Hulshof T, Howlett J. Glycemic response and health - A systematic review and meta-analysis: Relations between dietary glycemic properties and health outcomes. *Am J Clin Nutr*. 2008;87(1):258S-268S. doi:10.1093/ajcn/87.1.258S
130. Galbete C, Kröger J, Jannasch F, et al. Nordic diet, Mediterranean diet, and the risk of chronic diseases: The EPIC-Potsdam study. *BMC Med*. 2018;16(1):99. doi:10.1186/s12916-018-1082-y
131. Roswall N, Sandin S, Löf M, et al. Adherence to the healthy Nordic food index and total and cause-specific mortality among Swedish women. *Eur J Epidemiol*. 2015;30(6):509-517. doi:10.1007/s10654-015-0021-x
132. Astbury NM, Piernas C, Hartmann-Boyce J, Lapworth S, Aveyard P, Jebb SA. A systematic review and meta-analysis of the effectiveness of meal replacements for weight loss. *Obes Rev*. 2019;20(4):569-587. doi:10.1111/obr.12816
133. Heymsfield SB, Van Mierlo CAJ, Van Der Knaap HCM, Heo M, Frier HI. Weight management using a meal replacement strategy: Meta and pooling analysis from six studies. *Int J Obes*. 2003;27(5):537-549. doi:10.1038/sj.ijo.0802258
134. Wadden TA, West DS, Neiberg RH, et al. One-year weight losses in the look AHEAD study: Factors associated with success. *Obesity*. 2009;17(4):713-722. doi:10.1038/oby.2008.637
135. Sumithran P, Prendergast LA, Haywood CJ, Houlihan CA, Proietto J. Review of 3-year outcomes of a very-low-energy diet-based outpatient obesity treatment programme. *Clin Obes*. 2016;6(2):101-107. doi:10.1111/cob.12135
136. Mejia SB, Kendall CWC, Viguioliouk E, et al. Effect of tree nuts on metabolic syndrome criteria: A systematic review and meta-analysis of randomised controlled trials. *BMJ Open*. 2014;4(7):e004660. doi:10.1136/bmjopen-2013-004660
137. Flores-Mateo G, Rojas-Rueda D, Basora J, Ros E, Salas-Salvadó J. Nut intake and adiposity: Meta-analysis of clinical trials. *Am J Clin Nutr*. 2013;97(6):1346-1355. doi:10.3945/ajcn.111.031484
138. Afshin A, Micha R, Khatibzadeh S, Mozaffarian D. Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: A systematic review and meta-analysis. *Am J Clin Nutr*. 2014;100(1):278-288. doi:10.3945/ajcn.113.076901
139. Aune D, Keum N, Giovannucci E, et al. Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: Systematic review and dose-response meta-analysis of prospective studies. *BMJ*. 2016;353:i2716. doi:10.1136/bmj.i2716
140. Bao L, Cai X, Xu M, Li Y. Effect of oat intake on glycaemic control and insulin sensitivity: A meta-analysis of randomised controlled trials. *Br J Nutr*. 2014;112(3):457-466. doi:10.1017/S0007114514000889
141. Gijsbers L, Ding EL, Malik VS, De Goede J, Geleijnse JM, Soedamah-Muthu SS. Consumption of dairy foods and diabetes incidence: A dose-response meta-analysis of observational studies. *Am J Clin Nutr*. 2016;103(4):1111-1124. doi:10.3945/ajcn.115.123216
142. Imamura F, Fretts A, Marklund M, et al. Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies. *PLoS Med*. 2018;15(10). doi:10.1371/journal.pmed.1002670
143. Godos J, Tieri M, Ghelfi F, et al. Dairy foods and health: an umbrella review of observational studies. *Int J Food Sci Nutr*. 2019;1-14. doi:10.1080/09637486.2019.1625035
144. Knowler W, Fowler S, Hamman R, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. *Lancet*. 2009;374(9702):1677-1686. doi:10.1016/S0140-6736(09)61457-4.10-year
145. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and diabetes study. *Diabetes Care*. 1997;20(4):537-544. doi:10.2337/diacare.20.4.537
146. Tuomilehto J, Lindström J, Eriksson J, et al. Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance. *N Engl J Med*. 2008;344(18):1343-1350.
147. Lindström J, Peltonen M, Eriksson JG, et al. Improved lifestyle and decreased diabetes risk over 13 years: Long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). *Diabetologia*. 2013;56(2):284-293. doi:10.1007/s00125-012-2752-5
148. Warren JM, Smith N, Ashwell M. A structured literature review on the role of mindfulness, mindful eating and intuitive eating in changing eating behaviours: Effectiveness and associated potential mechanisms. *Nutr Res Rev*. 2017;30(2):272-283. doi:10.1017/S0954422417000154
149. Ulian MD, Pinto AJ, de Moraes Sato P, Benatti FB, de Campos-Ferraz, P. L Coelho D, Vessoni A. Effects of a new intervention based on the Health at Every Size approach for the management of obesity: The "Health and Wellness in Obesity" study. *PLoS One*. 2018;13(7). doi:10.1177/0260106017731260
150. Clifford D, Ozier A, Bundros J, Moore J, Kreiser A, Morris MN. Impact of Non-Diet Approaches on Attitudes, Behaviors, and Health Outcomes: A Systematic Review. *J Nutr Educ Behav*. 2015;47(2):143-155.e1. doi:10.1016/j.jneb.2014.12.002
151. Ruffault A, Czernichow S, Hagger MS, et al. The effects of mindfulness training on weight-loss and health-related behaviours in adults with overweight and obesity: A systematic review and meta-analysis. *Obes Res Clin Pract*. 2017;11(5):90-111.
152. Katterman SN, Kleinman BM, Hood MM, Nackers LM, Corsica JA. Mindfulness meditation as an intervention for binge eating, emotional eating, and weight loss: A systematic review. *Eat Behav*. 2014;15(2):197-204. doi:10.1016/j.eat-beh.2014.01.005
153. O'Reilly GA, Cook L, Spruijt-Metz D, Black DS. Mindfulness-based interventions for obesity-related eating behaviours: A literature review. *Obes Rev*. 2014;15(6):453-461. doi:10.1111/obr.12156
154. Carrière K, Khoury B, Günak MM, Knäuper B. Mindfulness-based interventions for weight loss: a systematic review and meta-analysis. *Obes Rev*. 2018;19(2):164-177. doi:10.1111/obr.12623
155. Rogers JM, Ferrari M, Mosely K, Lang CP, Brennan L. Mindfulness-based interventions for adults who are overweight or obese: a meta-analysis of physical and psychological health outcomes. *Obes Rev*. 2017;18(1):51-67. doi:10.1111/obr.12461
156. Peterson LA, Cheskin LJ, Furtado M, et al. Malnutrition in Bariatric Surgery Candidates: Multiple Micronutrient Deficiencies Prior to Surgery. *Obes Surg*. 2016;26(4):833-838. doi:10.1007/s11695-015-1844-y
157. Fieber JH, Sharoky CE, Wirtalla C, Williams NN, Dempsey DT, Kelz RR. The malnourished patient with obesity: a unique paradox in bariatric surgery. *J Surg Res*. 2018;232:456-463. doi:10.1016/j.jss.2018.06.056
158. Major P, Malczak P, Wysocki M, et al. Bariatric patients' nutritional status as a risk factor for postoperative complications, prolonged length of hospital stay and hospital readmission: A retrospective cohort study. *Int J Surg*. 2018;56:210-214. doi:10.1016/j.ijsu.2018.06.022
159. Johnson Stoklossa CA, Sharma AM, Forhan M, Siervo M, Padwal RS, Prado CM. Prevalence of sarcopenic obesity in adults with class II/III obesity using different diagnostic criteria. *J Nutr Metab*. 2017. doi:10.1155/2017/7307618
160. Godziuk K, Prado CM, Woodhouse LJ, Forhan M. Prevalence of sarcopenic obesity in adults with end-stage knee osteoarthritis. *Osteoarthritis Cartil*. 2019;27(12):1735-1745. doi:10.1016/j.joca.2019.05.026

161. Parrott J, Frank L, Rabena R, Craggs-Dino L, Isom KA, Greiman L. American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients. *Surg Obes Relat Dis*. 2017;13(5):727-741. doi:10.1016/j.soard.2016.12.018
162. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. *Am J Clin Nutr*. 2000;72(3):690-693. doi:10.1093/ajcn/72.3.690
163. Drincic AT, Armas LAG, Van Diest EE, Heaney RP. Volumetric dilution, rather than sequestration best explains the low vitamin D status of obesity. *Obesity*. 2012;20(7):1444-1448. doi:10.1038/oby.2011.404
164. Golzarand M, Hollis BW, Mirmiran P, Wagner CL, Shab-Bidar S. Vitamin D supplementation and body fat mass: a systematic review and meta-analysis. *Eur J Clin Nutr*. 2018;72(10):1345-1357. doi:10.1038/s41430-018-0132-z
165. Mallard SR, Howe AS, Houghton LA. Vitamin D status and weight loss: A systematic review and meta-analysis of randomized and nonrandomized controlled weight-loss trials. *Am J Clin Nutr*. 2016;104(4):1151-1159. doi:10.3945/ajcn.116.136879
166. Rafiq S, Jeppesen PB. Body mass index, vitamin d, and type 2 diabetes: A systematic review and meta-analysis. *Nutrients*. 2018;10(9):1182. doi:10.3390/nu10091182
167. Pathak K, Soares MJ, Calton EK, Zhao Y, Hallett J. Vitamin D supplementation and body weight status: A systematic review and meta-analysis of randomized controlled trials. *Obes Rev*. 2014;15(6):528-537. doi:10.1111/obr.12162
168. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JPA. Vitamin D and multiple health outcomes: Umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. *BMJ*. 2014;348:g2035. doi:10.1136/bmj.g2035
169. Ross AC, Manson JAE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. *J Clin Endocrinol Metab*. 2011;96(1):53-58. doi:10.1210/jc.2010-2704
170. Zhao L, Zhang X, Shen Y, Fang X, Wang Y, Wang F. Obesity and iron deficiency: A quantitative meta-analysis. *Obes Rev*. 2015;16(12):1081-1093. doi:10.1111/obr.12323
171. Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. *J Clin Endocrinol Metab*. 2016;101(4):1754-1761. doi:10.1210/jc.2015-3754
172. Maguire D, Talwar D, Shiels PG, McMillan D. The role of thiamine dependent enzymes in obesity and obesity related chronic disease states: A systematic review. *Clin Nutr ESPEN*. 2018;25:8-17. doi:10.1016/j.clnesp.2018.02.007
173. Wiebe N, Field CJ, Tonelli M. A systematic review of the vitamin B12, folate and homocysteine triad across body mass index. *Obes Rev*. 2018;19(11):1608-1618. doi:10.1111/obr.12724
174. Polivy J, Herman CP. Dieting and Binging. A Causal Analysis. *Am Psychol*. 1985;40(2):193-201. doi:10.1037/0003-066X.40.2.193
175. Keel PK, Baxter MG, Heatherton TF, Joiner TE. A 20-year longitudinal study of body weight, dieting, and eating disorder symptoms. *J Abnorm Psychol*. 2007;116(2):422-432. doi:10.1037/0021-843X.116.2.422
176. da Luz FQ, Hay P, Gibson AA, et al. Does severe dietary energy restriction increase binge eating in overweight or obese individuals? A systematic review. *Obes Rev*. 2015;16(8):652-665. doi:10.1111/obr.12295
177. Wadden TA, Foster GD, Sarwer DB, et al. Dieting and the development of eating disorders in obese women: Results of a randomized controlled trial. *Am J Clin Nutr*. 2004;80(3):560-568. doi:10.1093/ajcn/80.3.560
178. Yanovski S. Dieting and the development of eating disorders in overweight and obese adults. *Arch Intern Med*. 2000;160(17):2581-2589. doi:10.1001/archinte.160.17.2581
179. Sánchez A, Rojas P, Basfi-fer K, et al. Micronutrient Deficiencies in Morbidly Obese Women Prior to Bariatric Surgery. *Obes Surg*. 2016;26(2):361-368. doi:10.1007/s11695-015-1773-9
180. Dagan SS, Zelber-Sagi S, Webb M, et al. Nutritional Status Prior to Laparoscopic Sleeve Gastrectomy Surgery. *Obes Surg*. 2016;26(9):2119-2126. doi:10.1007/s11695-016-2064-9
181. Mechanick JI, Youdim A, Jones DB, et al. Clinical Practice Guidelines for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient—2013 Update: Cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Obesity. 2013;21(SUPPL. 1):S1-S27. doi:10.1002/oby.20461
182. Health Canada. Canada's Food Guide. Retrieved from <https://food-guide.canada.ca/en/>. <https://food-guide.canada.ca/static/assets/pdf/CFG-snapshot-EN.pdf>. Published 2019.
183. Health Canada. Canada's Dietary Guidelines: For Health Professionals and Policy Makers. Retrieved from <https://food-guide.canada.ca/en/guidelines>.
184. Wright G, Dawson B, Jalleh G, Law S. Impact of compliance on weight loss and health profile in a very low energy diet program. *Aust Fam Physician*. 2010;39(1):49-52.
185. Mulholland Y, Nicokavoura E, Broom J, Rolland C. Very-low-energy diets and morbidity: A systematic review of longer-term evidence. *Br J Nutr*. 2012;108(5):832-851. doi:10.1017/S0007114512001924
186. Benton D, Young HA. Reducing Calorie Intake May Not Help You Lose Body Weight. *Perspect Psychol Sci*. 2017;12(5):703-714. doi:10.1177/1745691617690878
187. Winkler JK, Schultz JH, Woehning A, et al. Effectiveness of a low-calorie weight loss program in moderately and severely obese patients. *Obes Facts*. 2013;6(5):469-480. doi:10.1159/000355822
188. Pal S, Ho S, Gahler RJ, Wood S. Effect on insulin, glucose and lipids in overweight/obese Australian adults of 12 months consumption of two different fibre supplements in a randomised trial. *Nutrients*. 2017;9(2):91. doi:10.3390/nu9020091
189. Thompson S V, Hannon BA, An R, Holscher HD. Effects of isolated soluble fiber supplementation on body weight, glycemia, and insulinemia in adults with overweight and obesity: A systematic review and meta-analysis of randomized controlled trials. *Am J Clin Nutr*. 2017;106(6):1514-1528. doi:10.3945/ajcn.117.163246
190. Jiao J, Xu JY, Zhang W, Han S, Qin LQ. Effect of dietary fiber on circulating C-reactive protein in overweight and obese adults: A meta-analysis of randomized controlled trials. *Int J Food Sci Nutr*. 2015;66(1):114-119. doi:10.3109/09637486.2014.959898
191. Hu X, Gao J, Zhang Q, et al. Soy fiber improves weight loss and lipid profile in overweight and obese adults: A randomized controlled trial. *Mol Nutr Food Res*. 2013;57(12):2147-2154. doi:10.1002/mnfr.201300159
192. Solah VA, Kerr DA, Hunt WJ, et al. Effect of fibre supplementation on body weight and composition, frequency of eating and dietary choice in overweight individuals. *Nutrients*. 2017;9(2):149. doi:10.3390/nu9020149
193. Santos NC, de Araujo LM, De Luca Canto G, Guerra ENS, Coelho MS, Borin M de F. Metabolic effects of aspartame in adulthood: A systematic review and meta-analysis of randomized clinical trials. *Crit Rev Food Sci Nutr*. 2018;58(12):2068-2081. doi:10.1080/10408398.2017.1304358
194. Meckling KA, Sherfey R. A randomized trial of a hypocaloric high-protein diet, with and without exercise, on weight loss, fitness, and markers of the Metabolic Syndrome in overweight and obese women. *Appl Physiol Nutr Metab*. 2007;32(4):743-752. doi:10.1139/H07-059
195. Wycherley TP, Moran LJ, Clifton PM, Noakes M, Brinkworth GD. Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized. *Am J Clin Nutr*. 2012;96(6):1281-1298. doi:10.3945/ajcn.112.044321.1
196. Evans EM, Mojtahedi MC, Thorpe MP, Valentine RJ, Kris-Etherton PM, Layman DK. Effects of protein intake and gender on body composition changes: A randomized clinical weight loss trial. *Nutr Metab*. 2012;9(1):55. doi:10.1186/1743-7075-9-55

197. Parr EB, Coffey VG, Cato LE, Phillips SM, Burke LM, Hawley JA. A randomized trial of high-dairy-protein, variable-carbohydrate diets and exercise on body composition in adults with obesity. *Obesity*. 2016;24(5):1035-1045. doi:10.1002/oby.21451
198. Ankarfeldt MZ, Ångquist L, Jakobsen MU, et al. Interactions of dietary protein and adiposity measures in relation to subsequent changes in body weight and waist circumference. *Obesity*. 2014;22(9):2097-2103. doi:10.1002/oby.20812
199. Maki KC, Rains TM, Kaden VN, Raneri KR, Davidson MH. Effects of a reduced-glycemic-load diet on body weight, body composition, and cardiovascular disease risk markers in overweight and obese adults. *Am J Clin Nutr*. 2007;85(3):724-734. doi:10.1093/ajcn/85.3.724
200. Ebbeling CB, Leidig MM, Feldman HA, Lovesky MM, Ludwig DS. Effects of a low-glycemic load vs low-fat diet in obese young adults: A randomized trial. *J Am Med Assoc*. 2007;297(19):2092-2102. doi:10.1001/jama.297.19.2092
201. Shiau JY, So DYF, Dent RR. Effects on Diabetes Medications, Weight and Glycated Hemoglobin Among Adult Patients With Obesity and Type 2 Diabetes: 6-Month Observations From a Full Meal Replacement, Low-Calorie Diet Weight Management Program. *Can J Diabetes*. 2018;42(1):56-60. doi:10.1016/j.jcjd.2017.03.006
202. Koohkan S, Schaffner D, Milliron BJ, et al. The impact of a weight reduction program with and without meal-replacement on health related quality of life in middle-aged obese females. *BMC Womens Health*. 2014;14(1):45. doi:10.1186/1472-6874-14-45
203. Daubenmier J, Moran PJ, Kristeller J, et al. Effects of a mindfulness-based weight loss intervention in adults with obesity: A randomized clinical trial. *Obesity*. 2016;24(4):794-804. doi:10.1002/oby.21396
204. Mason AE, Epel ES, Kristeller J, et al. Effects of a mindfulness-based intervention on mindful eating, sweets consumption, and fasting glucose levels in obese adults: data from the SHINE randomized controlled trial. *J Behav Med*. 2016;39(2):201-213. doi:10.1007/s10865-015-9692-8

Medical Nutrition Therapy in Obesity Management

Brown J, Clarke C, Johnson Stoklossa C, Sievenpiper J. Canadian Adult Obesity Clinical Practice Guidelines: Medical Nutrition Therapy in Obesity Management. Available from: <https://obesitycanada.ca/guidelines/nutrition>

Appendix

BACKGROUND

The European Association for the Study of Obesity (EASO) collaborated with Obesity Canada (OC) in efforts to create a new European Dietary Guideline of Obesity Management, using the Medical Nutrition Therapy (MNT) chapter of the 2020 Canadian Adult Obesity Clinical Practice Guidelines.

The initial literature review and quality assessment was conducted by the McMaster Evidence Review and Synthesis Team (MERST) between January 2006 and June 2018, identifying n=16,191 articles with n=161 studies used for critical appraisal to support 20 recommendations using the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) framework.

CURRENT FINDINGS

MERST performed an updated literature review between November 2018 and March 2021, resulting in 42,015 citations. After removing repeated articles and title and abstract screening, 110 full text articles were screened by the Canadian MNT authors (CC and CJS) who identified n=57 studies. These studies were critically appraised by MERST in line with the methodology of the current Canadian MNT chapter. Members of the European Dietary Guideline committee then compared the updated evidence to the MNT chapter recommendations. Two areas were identified providing updated evidence to support existing recommendations (table 1). Under recommendation 4h, pertaining to the use of partial meal replacements; 5 updated studies/reviews with mixed levels of evidence (2 x level 1a and 3 x level 2) were found in people living with obesity. Additionally, recommendation 4i, related to updated evidence on intermittent fasting, identified 7 studies/reviews with mixed levels of evidence (2x Level 2 and 5x level 1a evidence).

The authors of the MNT Chapter of the Canadian Adult Obesity Clinical Practice Guideline reviewed the summary report by the European Dietary Guideline committee, including the updated evidence on meal replacements and intermittent fasting (table 1). Canadian MNT authors (JB, CC, CJS, JS) analyzed whether the updated evidence would change current recommendations or significantly affect clinical practice.

RECOMMENDATIONS

No changes to the existing recommendations in the Medical Nutrition Therapy Chapter of Canadian Adult Obesity Clinical Practice Guideline are required at this time. The evidence found in this review does not affect the recommendations made for clinical practice. This appendix serves as a resource to provide readers with updated references conducted in the 2021 MERST literature review in partnership with EASO and OC.

Table 1: Summary of MNT Recommendations

Current Recommendations ^a	Updated Evidence Identified ^b	Canadian MNT Author Recommendations	Rationale
<p>Adults living with obesity can consider any of the multiple medical nutrition therapies to improve health-related outcomes, choosing the dietary patterns and/or food-based approaches that support their best long-term adherence:</p> <p>4h: Partial meal replacements (replacing one to two meals/day as part of a calorie-restricted intervention) to reduce body weight, waist circumference, blood pressure and improve glycemic control (Level 1a, Grade B).¹</p>	<p>1 Rohling, M., et al² (level 2)</p> <p>Halle, M., et al³ (level 2)</p> <p>Astbury, N., et al⁴ (level 1a)</p> <p>Guo, X., et al⁵ (level 2)</p> <p>Noronha, J.C., et al⁶ (level 1a)</p>	<p>We recommend 4h maintain a Level 1a, Grade B recommendation and include updated references in an appendix linked to the MNT chapter.</p>	<p>Literature review conducted in 2021 reflects mixed levels of evidence (2x level 1a and 3x level 2), maintaining a level 1a, Grade B recommendation.</p> <p>The evidence does not significantly affect clinical practice, therefore, changes to the current recommendation is not warranted at this time.</p> <p>Future revisions/updates of this recommendation should separate the levels of evidence based on outcomes (i.e. body weight, waist circumference, blood pressure, glycemic control, etc).</p>
<p>4i: Intermittent or continuous calorie restriction achieved similar short-term body weight reduction (Level 2a, Grade B).⁷</p>	<p>Enriquez Guerrero, A., et al⁸ (level 1a)</p> <p>Park, J., et al⁹ (level 1a)</p> <p>Yan, S., et al¹⁰ (level 1a)</p> <p>Headland, M. L., et al¹¹ (level 2)</p> <p>Sundfør T. M., et al¹² (level 2)</p> <p>Roman, Y.M., et al¹³ (level 1a)</p> <p>Vitale, R. & Kim, Y. et al¹⁴ (level 1a)</p>	<p>We recommend 4i delay an update until 2022 to support a comprehensive review of literature. Current recommendation should include updated references in an appendix linked to the MNT chapter.</p>	<p>The evidence does not significantly affect clinical practice, therefore, changes to the current recommendation is not warranted at this time.</p> <p>The follow-up timeline for weight reduction using intermittent fasting remains short-term. An unpublished network meta-analysis has compared four types of intermittent fasting, alternate day fasting, 5:20 fasting, time-restricted fasting compared to continuous energy restriction and found no significant differences that would affect our recommendation. Therefore, we would suggest delaying this update until 2022 as further evidence in intermittent fasting is published, including a network meta-analysis that would capture these studies.</p> <p>Consideration to separate the levels of evidence based on outcomes (i.e. body weight, waist circumference, blood pressure, glycemic control, etc) may be indicated in future updates of the MNT chapter.</p>

^a Based on studies critically appraised between June 2006 and June 2018 in Brown J, Clarke C, Johnson Stoklossa C, Sievenpiper J. Canadian Adult Obesity Clinical Practice Guidelines: Medical Nutrition Therapy in Obesity Management. Available from: <https://obesitycanada.ca/guidelines/nutrition>. Accessed [November 30, 2021].

^b Based on studies critically appraised between November 2018 - March 2021 by McMaster Evidence Review and Synthesis Team (MERST)

References

1. Noronha JC, Nishi SK, Braunstein CR, et al. The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight / Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Diabetes Care*. 2019;42(5):767-776.
2. Rohling, M., Stensitzky, A., Oliveira, C. L. P., Beck, A., Braumann, K. M., Halle, M., Fuhrer-Sakel, D., Kempf, K., McCarthy, D., Predel, H. G., Schenkenberger, I., Toplak, H., Berg, A. (2021). Effects of a protein-rich, low-glycaemic meal replacement on changes in dietary intake and body weight following a weight-management intervention-the ACOORH trial *Nutrients*, 13(2):1-11.
3. Halle M, Röhling M, Banzer W, Braumann KM, Kempf K, McCarthy D, Schaller N, Predel HG, Scholze J, Führer-Sakel D, Toplak H, Berg A; ACOORH study group. Meal replacement by formula diet reduces weight more than a lifestyle intervention alone in patients with overweight or obesity and accompanied cardiovascular risk factors-the ACOORH trial. *Eur J Clin Nutr*. 2021 Apr;75(4):661-669. doi: 10.1038/s41430-020-00783-4.
4. Astbury NM, Piernas C, Hartmann-Boyce J, Lapworth S, Aveyard P, Jebb SA. A systematic review and meta-analysis of the effectiveness of meal replacements for weight loss. *Obes Rev*. 2019 Apr;20(4):569-587. doi: 10.1111/obr.12816.
5. Guo X, Xu Y, He H, Cai H, Zhang J, Li Y, Yan X, Zhang M, Zhang N, Maddala RL, Nicodemus-Johnson J, Ma G. Effects of a Meal Replacement on Body Composition and Metabolic Parameters among Subjects with Overweight or Obesity. *J Obes*. 2018 Dec 26;2018:2837367. doi: 10.1155/2018/2837367.
6. Noronha JC, Nishi SK, Braunstein CR, Khan TA, Blanco Mejia S, Kendall CWC, Kahleová H, Rahelić D, Salas-Salvadó J, Leiter LA, Sievenpiper JL. The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Diabetes Care*. 2019 May;42(5):767-776. doi: 10.2337/dc18-2270
7. Cioffi I, Evangelista A, Ponzio V, et al. Intermittent versus continuous energy restriction on weight loss and cardiometabolic outcomes: a systematic review and meta-analysis of randomized controlled trials. *J Transl Med*. 2018;16(1):371. doi:10.1186/s12967-018-1748-4
8. Enríquez Guerrero, A., San Mauro Martín, I., Garicano Vilar, E. et al. Effectiveness of an intermittent fasting diet versus continuous energy restriction on anthropometric measurements, body composition and lipid profile in overweight and obese adults: a meta-analysis. *Eur J Clin Nutr* 75, 1024–1039 (2021). <https://doi.org/10.1038/s41430-020-00821-1>
9. Park J, Seo YG, Paek YJ, Song HJ, Park KH, Noh HM. Effect of alternate-day fasting on obesity and cardiometabolic risk: A systematic review and meta-analysis. *Metabolism*. 2020 Oct;111:154336. doi: 10.1016/j.metabol.2020.154336
10. Yan S, Wang C, Zhao H, Pan Y, Wang H, Guo Y, Yao N, Li B, Cui W. Effects of fasting intervention regulating anthropometric and metabolic parameters in subjects with overweight or obesity: a systematic review and meta-analysis. *Food Funct*. 2020 May 1;11(5):3781-3799. doi: 10.1039/d0fo00287a.
11. Headland ML, Clifton PM, Keogh JB. Effect of intermittent compared to continuous energy restriction on weight loss and weight maintenance after 12 months in healthy overweight or obese adults. *Int J Obes (Lond)*. 2019 Oct;43(10):2028-2036. doi: 10.1038/s41366-018-0247-2. Epub 2018 Nov 23. Erratum in: *Int J Obes (Lond)*. 2019 Apr;43(4):942. PMID: 30470804.
12. Sundfjør TM, Tonstad S, Svendsen M. Effects of intermittent versus continuous energy restriction for weight loss on diet quality and eating behavior. A randomized trial. *Eur J Clin Nutr*. 2019 Jul;73(7):1006-1014. doi: 10.1038/s41430-018-0370-0
13. Roman YM, Dominguez MC, Easow TM, Pasupuleti V, White CM, Hernandez AV. Effects of intermittent versus continuous dieting on weight and body composition in obese and overweight people: a systematic review and meta-analysis of randomized controlled trials. *Int J Obes (Lond)*. 2019 Oct;43(10):2017-2027. doi: 10.1038/s41366-018-0204-0.
14. Vitale R, Kim Y. The Effects of Intermittent Fasting on Glycemic Control and Body Composition in Adults with Obesity and Type 2 Diabetes: A Systematic Review. *Metab Syndr Relat Disord*. 2020 Dec;18(10):450-461. doi: 10.1089/met.2020.0048